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1.0 EXECUTIVE SUMMARY 
1.1 Study Overview 
Free trade agreements (FTAs) have the declared aim of seeking to increase global trade and 
promote economic growth. Historically, economic growth has led to improved population 
health. Yet this link is now weakening, and attention is being focussed on assessing the effect of 
FTAs on health and the ability of government to mitigate against negative impact.  Within this 
context, this study presents an assessment of the health impact of the proposed FTA between 
the United States and the European Union.  
 
The proposed Transatlantic Trade and Investment Partnership (TTIP) between the US 
and the EU constitutes the largest ever FTA of its kind.  
 
Although the TTIP mandate has recently been made public, access to negotiating texts 
remains limited and it is apparent that much detail on TTIP is still to be agreed. With 
this in mind the aims of this rapid evidence assessment are: 
 
▪ To summarise and critically evaluate available evidence on the health related 
risks and benefits of TTIP;  
▪ To make an assessment as to the overall health impact that TTIP may be 
expected to have; and  
▪ To provide guidelines for the European public health community about priorities 
that they could be focussing on, as they respond to the TTIP negotiating 
process.  
 
The study is based upon a structured and systematic rapid evidence assessment and a 
targeted stakeholder engagement process, commissioned to run over an eight-week 
time period during August and September 2014.  
1.2 TTIP in Context 
TTIP forms part of a widening international trade agenda that has moved from tariff reduction 
to trade liberalisation, investment protection and regulatory reform. In terms of scale, scope 
and remit the TTIP represents a significant new development in European trade policy and 
regulatory reform.  
 
There is currently a mosaic of pre-existing Bilateral Investment Treaties (BITs) between 
individual Member States and the US, each of which varies in form and content. Nine 
current Member States including Poland, the Czech Republic and Croatia have a 
current BIT with the United States. The TTIP is designed to replace these with a single 
FTA covering all 28 Member States of the European Union.  
 
There are links between the proposed TTIP and post-war international trade 
liberalisation that saw the establishment of the World Trade Organisation (WTO), the 
subsequent development of the General Agreement on Tariffs and Trade (GATT) and 
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the General Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS).  
 
The reform programme initially focussed on tariff reductions and is commonly 
recognised as having underpinned a period of rapid global economic growth. This 
agenda has now been expanded to include consideration of a range of non-tariff 
related regulatory issues. Failure of the 2001 Doha round of the GATT process to 
reach universal common agreement on non-tariff issues then heralded a tactical 
realignment with the development of a parallel reform track based upon interlocking 
multilateral level trade agreements. 
 
The TTIP negotiations were initiated at the G8 meeting in Northern Ireland in 2013. For 
the US, they formed a further strategic FTA to the North Atlantic Free Trade Agreement 
(NAFTA) and the Trans Pacific Partnership (TPP). The TTIP also shares similar policy 
goals and negotiating structure to the EU-Canada Comprehensive Economic and 
Trade Agreement (CETA) that was instigated in May 2009. TTIP and CETA represent 
the first FTAs to be negotiated following the signing of the Lisbon Treaty in December 
2009. This treaty had extended the EU’s powers within the area of foreign and 
domestic investment (FDI) and introduced the requirement for the European Parliament 
to ratify FTAs. 
 
Evidence suggests that both the US and the EU are seeking regulatory reform from 
TTIP, and are additionally viewing the TTIP as a vehicle for post 2008 recession 
recovery.  
 
TTIP is considered by proponents and opponents to be fundamentally different to other 
FTAs on the basis that: 
 
▪ The majority of projected gains are to accrue from regulatory as opposed to 
tariff reform; 
▪ US and EU trade representatives describe it as being a blueprint for future 
FTAs; and 
▪ It is described as being a ‘living agreement’ that will see structures established 
to oversee on-going regulatory reform subsequent to initial ratification. 
 
For proponents, these three features will help to deliver growth alongside improved 
regulation, whilst critics argue that they could lead to a reduction in regulatory 
standards as well as restricting the ability of the state to regulate in the public interest. 
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1.3 Overall Impact of TTIP  
Proponents estimate that benefits in excess of €200bn could be realised within two decades of 
the TTIP agreement being signed, the majority of which would come from non-tariff based 
reform. Critics have challenged the methods and assumptions used to develop these estimates, 
and evidence from other FTAs suggests that economic impact is difficult to measure and 
attribute. Consequently, projections of net economic benefit should be treated with caution.  
 
Studies undertaken by the European Commission suggest overall economic gains 
accruing from TTIP would equate to a one off increase in European GDP in the range 
of 0.3% to 1.3%, with a similar level of gain for the United States’ economy.  
 
There is an established link between GDP growth and improved population health, 
however this needs to be set against recent assessments which posit a weakening of 
the effect size, most particularly for More Developed Countries (MDCs). The manner in 
which additional wealth is utilised in MDCs is also of note. Research suggests that it is 
key in determining whether it will have a positive or negative effect on living standards 
and health status.  
 
Critics have also challenged the reliability of the assumptions used to underpin the 
economic modelling and contend that the social costs of regulatory change and loss of 
state revenue have not been fully accounted for.  
 
Outside of Europe and the US, studies examining the potential impact of TTIP contend 
trade between Less Developed Countries (LDC) and the EU to be most at risk from 
TTIP. However, the overall impact looks to be limited as key sectors for LDCs such as 
textiles are unlikely to be impacted.  
1.4 Thematic Impact of TTIP  
The health impact of TTIP will emanate from both goods and services - particularly food, 
pharmaceuticals and the delivery of health services. Few overall specific health benefits were 
identified, while the scale and impact of disbenefits will be dependent on a highly complex 
interplay of factors.  
 
TTIP is divided into a number of chapters, the following of which have been identified 
as being most likely to have aspects that could impact upon health.  
1.4.1 Trade in Goods  
There appears to be limited health related benefits that could accrue from the TTIP in relation 
to trade in goods, while the largest single health risk will arise from tariff reductions leading to 
increased consumption of unhealthy foods. 
 
Proposed reductions in tariffs on processed foods have been projected to generate one 
of the largest percentage increases in imports of goods by sector. If existing tariffs were 
to be significantly reduced or eliminated and current restrictions lifted, then evidence 
suggests imports into the EU of US agri-food produce could double by 2025, albeit 
from a low baseline. Whilst this may have a positive economic impact on consumers by 
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reducing some food costs, evidence suggests that this could be undermined by the 
negative health impact of increasing the availability and reducing the price of unhealthy 
foods, which are particularly price sensitive.  
 
Secondly, TTIP could lead to increased imports of Genetically Modified (GM) crops and 
produce, which are currently subject to restrictions, as well as hormone treated beef, 
the import of which is currently illegal within the European Union. EU negotiators 
continue to state that the regulatory position of these goods will not change as a result 
of TTIP, even though the evidence base on their health impact remains highly 
contested. 
 
1.4.2 Technical Barriers to Trade (TBT)  
Health related TBTs primarily relate to pharmaceuticals and agri-food. TBTs could 
positively impact on health if pharmaceutical regulatory efficiencies were realised, yet 
such benefits might be offset by concomitant increases in pharmaceutical costs 
resulting from other provisions within the TBT chapter. No estimates of the overall 
impact were identified during the evidence review. 
 
The importance of the pharmaceutical industry to the European and US economies is 
well established, and a particular focus for the European Commission is to address the 
decline in market share of European companies during the first decades of the new 
millennium.  
 
Within the pharmaceuticals sector there is a broad consensus that the commitment to 
regulatory convergence within TTIP could result in significant efficiencies in relation to 
the authorisation of clinical trials data. The potential for increased cooperation between 
the European Medicines Agency (EMA) and the Federal Drugs Administration (FDA) 
could result in reduced duplication of processes and improved research cooperation. 
This could enable medicines getting to market more quickly. However, there are also 
concerns that TBT provisions within TTIP could impact on transparency, with some 
groups arguing that industry would be more able to limit the sharing of relevant data, 
additionally affecting member state pricing and reimbursement policies and practices.  
 
The determination of pharmaceutical prices remains a highly complex process. 
Consequently, whilst two measures have been identified which could put an upward 
pressure on prices and one that could apply a downward pressure, no estimates of 
their likely overall impact were identified during the review.   
 
Agri-food could be impacted primarily in relation to food labelling, where the TBT 
chapter of TTIP could provide an additional platform for industry to challenge 
regulations. However, evidence of WHO TBT provisions being used to challenge the 
right to regulate demonstrate that the ability to challenge public health related food 
labelling will remain, whatever provisions are finally agreed in TTIP. 
 
1.4.3 Sanitary and Phytosanitary Issues (SPS) 
Short- to medium-term health-related risks associated with the SPS chapter of TTIP 
appear to be limited. Whilst there are different food safety systems operating in the US 
and the EU, the evidence of there being differential health impact is inconclusive. 
Although increased cross-border trade could increase health risks, it is difficult to 
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estimate overall potential impact. Longer term rationalisation of SPS provisions offer 
both opportunities and risks. 
 
Evidence from other FTAs suggests that increased cross border trade in products with 
different regulatory systems and standards could increase the risk of outbreaks of 
diseases such as Hepatitis A, although comparability is limited. 
 
TTIP is unlikely to see an increase in imports of goods that do not meet current EU 
standards, such as hormone treated beef, as this is a long standing issue which is 
unlikely to be resolved at this juncture. Even if restrictions were lifted, the evidence on 
potential harm is inconclusive and remains contested.  
 
There have been repeated assurances from negotiators that TTIP will not require either 
party to lower its regulatory standards. The focus appears to be on mutual recognition 
of existing standards. No evidence was identified from other trade agreements of there 
having been a levelling up of standards.  
1.4.4 Trade in Services 
The main health focus within the Trade in Services chapter relates to public 
procurement and the exclusion of health services from TTIP. The impact of 
privatisation on efficiency, quality and employment terms and conditions is well 
evidenced. Consequently, as the boundaries between ‘social’ and ‘commercial’ 
services continue to blur, the precise wording of any ‘hard’ or ‘soft’ exclusion will be of 
importance. The greatest consequence would be to those Member States that choose 
not to explicitly exclude their health services from TTIP. 
 
The following two areas of risk have been identified from the evidence review: 
 
▪ That TTIP will require publicly run health services to be opened up to 
competition from private sector healthcare providers; and 
▪ That a ‘ratchet clause’ and negative listing in TTIP would preclude the 
possibility of privatised public services being returned to state operation.  
 
Underpinning the concern about health services is the argument that health, alongside 
other public services, are not suitable for traditional market competition and as such 
should be fully or partially excluded from the trade in services provisions within TTIP. 
Those studies that have provided evidential support for such assertions cite issues 
such as inefficiencies arising from the contracting process for outsourced delivery of 
care.     
 
EU negotiators have made a clear commitment that there will be an exemption for 
public services from TTIP, and that this exclusion will include publically run health 
services. However, it appears that TTIP will include a soft exclusion or ‘exemption’ 
rather than a hard exclusion or ‘carve out’. 
 
Individual Member States will have to make an explicit decision whether to include or 
exclude their national health services. At Member State, level the UK is one country 
where evidence suggests that the government may not seek to exclude all of its health 
services.  
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The second associated public procurement issue relates to renationalisation and 
whether the public procurement provisions, when linked to investor protection, could 
‘lock in’ current or future privatisation through the use of a ‘ratchet clause’. The EU 
negotiating team have issued further assurances that the ability of Government to 
determine its own policy would be protected. However, much will rely on the position 
with regard to ISDS (see section below), and the final decision of Member States with 
regard to seeking the exclusion of health services from TTIP. 
 
Finally, TTIP could potentially impact on health were there to be increased mutual 
recognition of qualifications. However the final decision as to whether or not to accept 
overseas qualifications will rest with individual Member States. It should also be noted 
that TTIP does not include any provisions relating to freedom of movement.  
 
1.4.5 Investor Protection 
The single most contested aspect of the TTIP negotiations relates to the proposed 
inclusion of an Investor to State Dispute Resolution (ISDS) arbitration system. 
Evidence of the current operation of ISDS provides only limited substantiation to the 
assertion that it constitutes a significant new area of risk to public health regulation. At 
the same time, the ability to legally challenge public health policy will remain in other 
international law even if a final decision is taken to remove or fundamentally amend the 
investor protection provisions in TTIP. 
 
The challenge of ISDS is summarised as follows: 
 
▪ ISDS allows claims for the expropriation of investor profits; 
▪ ISDS can lead to ‘regulatory chill’ as governments may desist from undertaking 
regulatory reform for fear of legal action; 
▪ ISDS takes arbitration out of national legal frameworks to third party arbitration 
tribunals; 
▪ There has been a significant increase in ISDS cases over the last years; 
▪ A small proportion of ISDS cases have related to core health service issues; 
and 
▪ A number of countries are now withdrawing ISDS from existing and proposed 
BITs. 
 
The counter argument is that: 
 
▪ Assessment of ISDS cases to date demonstrates that more were concluded for 
government than business, and more have been settled prior to coming to 
court; 
▪ A majority of ISDS cases to date have been taken within the EU, not the US; 
▪ The majority of ISDS cases have been concluded in favour of national 
governments; 
▪ Awards made have been significantly below the level of initial claims; 
▪ ISDS is already present in BITs between EU Member States and the United 
States, yet there has not been an ISDS case between the US and the EU15 to 
date; and 
▪ The ISDS provisions proposed for TTIP provide increased protection against 
inappropriate claims than existing ISDS provisions within BITs. 
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There are very few empirical studies relating to the potential impact of ISDS, but those 
such as the study for the Netherlands Government believe the overall risk to be 
overstated, with evident potential to militate against what risk there is. 
 
The inclusion of ISDS is currently the subject of a formal Public Consultation exercise 
that has been instigated by the European Commission, while Member States such as 
Germany are now publically airing doubts about its inclusion.  
 
It currently appears likely that ISDS will either be withdrawn from TTIP or will be subject 
to further revision that could include greater transparency, revision of the extra-judicial 
process and/or the inclusion of additional safeguards against potential misuse. 
Evidence suggests that the exclusion of ISDS would have a limited impact on 
investment levels. 
 
1.4.6 Intellectual Property 
Intellectual property (IP) may have a range of health related impacts, of which the 
pharmaceutical impact is likely to be the most important. Whilst there is currently a high 
level of accord between the two trading blocs, there remain some differences. If TTIP 
were to fully align to US provisions on IP, it may positively impact on innovation yet 
could also create an upward cost pressure. 
 
Given that pharmaceutical costs represent 1.5% of European GDP, any increase in IP 
protection arising from TTIP might have a tangible impact on healthcare costs. The 
health impact of the intellectual property chapter in part relates to the issue of patent 
protection and regulatory data protection (RDP) for pharmaceuticals. There is close 
alignment between the US and EU but some differences remain. For example there is 
no continuity on how prior user rights are defined, how patent applications are handled 
or even how patentability is determined. 
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1.4.7 Regulatory Cooperation and Reform 
As a ‘living agreement’, regulatory cooperation and reform is likely to be an integral on-
going aspect of the TTIP agenda. However there is insufficient evidence to make prior 
determination as to whether long term regulatory cooperation and alignment would 
have a beneficial or detrimental health impact. 
 
The TTIP sets out an ongoing commitment to increased regulatory alignment, but at 
the same time asserts that it will not result in any reduction of current standards.  
 
Given the need to generate both direct and indirect savings from the regulatory reform 
process, many stakeholders posit that an initial focus on achieving reform through 
mutual recognition and increased regulatory alignment will be superseded by one that 
seeks a deeper level of regulatory convergence.   
 
The two broad approaches to risk management through regulation are the evidence-
based and precautionary approaches. Commonly, the US is caricatured as adopting 
US the former and the EU the latter. This is too simplistic and the TTIP does not out-
and-out favour either approach. However, some commentators believe the commitment 
to “efficient and cost-effective” regulation could in practice present a significant 
challenge to the precautionary approach. The consequent impact of moving from a 
precautionary to a more evidenced-based risk approach is equally difficult to predict on 
the basis of current evidence. 
 
1.4.8 Regulatory Health Policy Space 
Public health regulation is now increasingly focussed on non-communicable disease 
issues. TTIP presents only limited additional legal scope for stakeholders to challenge 
the ability of government to regulate in this area. 
 
Regulation in support of public health goals is a common feature within the US and EU, 
with many aspects decentralised to national, regional and municipal level. Within this 
context a number of commentators contend that TTIP would open aspects of public 
health regulation to legal challenge. In support of this, international examples have 
been highlighted which relate to the labelling and advertising of food, alcohol and 
tobacco.  
 
An assessment of the evidence suggests the principal regulatory risk to emanate from 
ISDS provisions within the TTIP, with such risk being both direct and indirect. The 
direct and indirect risk are respectively termed:  
 
▪ Regulatory snare – whereby a government finds itself involved in often long 
term and resource intensive legal process to defend itself from a claim; and 
▪ Regulatory chill – whereby a government is dissuaded from initiating or 
continuing with a particular regulatory change for fear of a potential claim and 
its consequences. 
 
The evidence review was able to evidence the ‘snare’ impact of claims on government, 
but only limited evidence of regulatory chill was identified. 
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Whilst some commentators believe the TTIP constitutes a risk to the future right to 
regulate, the evidence review has not established significant additional risk to that 
already presented by existing national, European and international trade law. 
1.5 TTIP Governance and Accountability 
There has only been limited stakeholder engagement in the TTIP negotiating process 
and limited transparency, although it appears to be a more open process than with 
prior FTAs. TTIP also includes a developed governance structure, reflecting the 
commitment to the establishment of a ‘living agreement’. 
 
Public opinion polls have been broadly supportive of TTIP, but there is increasing 
evidence of citizen concerns relating to particular issues such as ISDS and the 
potential outsourcing of health services.  
 
There has also been a recently failed attempt to establish a Citizens Initiative, which 
appeared close to achieving the required one million registered EU citizens to 
challenge both the TTIP and CETA negotiating process.   
 
TTIP has initially followed a common approach of FTAs in being subject to limited 
public scrutiny, although the EC has undertaken specific public consultation exercises 
on the issues of ISDS and the potential impact of TTIP on small- and medium-size 
enterprises (SMEs).  
 
The negotiating mandate for TTIP has recently been declassified and civil society 
representatives have been given a limited advisory role on a specially established 
group. TTIP also envisages the establishment of an intra-regulatory governance 
structure, with sub-committees for chapters such as SPS as well as for broader 
regulatory cooperation. These are likely to be of increasing importance over time, given 
the unique ‘living agreement’ status given to the TTIP by both negotiating teams. 
1.6 Study Recommendations  
There remains a strong commitment to concluding the TTIP negotiations, and as such 
stakeholder groups should take a proactive, systematic, engaged and evidenced based 
approach that is focussed on supporting a positive growth agenda, protecting the right 
to regulate and mitigating areas of potential risk.  
 
The suggested response of civil society organisations should involve focus, 
engagement and challenge and should recognise that TTIP forms just one element of a 
wider platform of international trade law, which is increasingly focussed on non-tariff 
issues.  
 
▪ Focus - Should be put on those chapters of TTIP that are of the greatest 
importance to health such SPS, TBT, IP and Services, as well as to broader 
regulatory themes such as the precautionary principle.  
▪ Engagement - There is a need for the public health community to continue to 
seek to positively engage in the TTIP development process, so as to ensure the 
common understanding of regulatory boundaries. 
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▪ Challenge - Our assessment has identified the absence of systematic 
assessment of the health impact of each of the relevant chapters within TTIP. 
Increased use of economic impact assessment tools and techniques could help 
to address this issue and provide a more robust evidence base. 
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2.0 Study Overview 
The EU and the US constitute the two largest trading entities in the world. As such, 
current plans to establish TTIP as an FTA is of importance not only to their own 
citizens, but also to the global community as a whole.  
2.1 Study Aims and Objectives 
The research study provides an assessment of major trends in free trade policy. It 
traces the development of bi-lateral agreements and the expansion of the remits of 
FTAs to include policies on non-tariff and investment protection and arbitration issues. 
There is also an assessment of broader global trade governance matters as they relate 
to health policy.  
 
The study aims and objectives were as follows: 
 
§ Understanding the historical evolution of free trade agreements and their 
potential impact upon health status and healthcare policies and practices; 
§ Critically examining the aims and objectives of TTIP; 
§ Categorising and quantifying the major health sector and public health impacts 
of FTAs to date; 
§ Assessing, on the basis of the information available, the potential health and 
healthcare policy and practice benefits from the implementation of a finalised 
TTIP agreement; 
§ Estimating the overall value of such benefits that could result; 
§ Identifying the areas of risk within the health domain that might be associated 
with the implementation of a finalised TTIP agreement;  
§ Giving particular consideration to the interface between health policy and public 
health, particularly in relation to foods as well as non-alcoholic sugar-sweetened 
beverages, alcohol and tobacco; and  
§ In the light of the above, developing a public health focused strategic response 
framework for EPHA and its members. 
2.2 Research Programme 
The research study was commissioned to be undertaken over a ten-week period, 
utilising secondary evidence review, stakeholder engagement1 and impact assessment 
approaches. 
 
The evidence review has been web based using standard and academic search 
engines, with a selection process that has sought to identify relevant, rational and 
evidence-based academic journal articles as well as grey literature representing the 
views of as broad a range of stakeholders as possible. 
 
                                                             
1 Stakeholder formally interviewed were Robert Stumberg, Professor of Law and Director 
Harrison Institute for Public Law | Georgetown Law, Jaydee Hanson Senior Policy Analyst Center for Food Safety, and Benn 
McGrady, PhD Project Director, Initiative on Trade, Investment and Health O'Neill Institute for National and Global Health Law. 
In addition the Research Director has attended a number of conferences on TTIP in the Brussels and Washington and has 
presented on the study at two conferences including the EPHA Annual Conference in November 2014. 
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The rapid evidence assessment has been drawn together into an EPHA Conference 
presentation in September 2014 and a final report in December 2014.  
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3.0 International Trade and Health in Context 
A widening of the agenda to trade liberalisation investment protection and regulatory 
reform has followed a successful programme of international tariff reductions. As 
attempts to introduce such reforms at a global level have faltered, countries have 
sought to advance these goals through a series of larger bi-lateral and multilateral 
investment treaties. TTIP would be one of the largest such tariff, investment and 
regulatory treaties to be agreed. 
3.1 Free Trade Law 
The classical case for free trade was first forwarded by Adam Smith, in a riposte to the 
mercantilism of the day. At its heart is the idea that a wider market allows for deeper 
specialisation and division of labour. David Ricardo further developed the argument, 
stating that international trade is not driven by absolute costs of production, but by 
opportunity costs. A closer look at the efficiency gains of free trade highlights the 
intensification of competition over the realisation of economies of scale. On this basis 
free trade must be considered an essential element in spurring innovation and growth. 
This in turn helps ground the case for agreements such as TTIP, where a broader and 
deeper market leads to productivity gains and, indirectly, increased welfare for all.  
 
The underlying argument put forward by Ricardo has been further developed by those 
who believe free trade to be a necessary but not in itself a sufficient precondition for 
prosperity2. The argument is forwarded that in order to reap maximum gains, free trade 
must be accompanied by provisions such as property rights and the rule of law, as well 
as through the provision of stable macroeconomic policies. As will be discussed later, 
TTIP is deemed to be a more expansive FTA because it is focussed on these 
accompanying elements of market reform.  
 
This current debate on the value of TTIP can be linked to an on-going and broader 
ideological debate between the free market and social market models. The social 
market model takes a much more active stance on regulatory measures. According to 
the proponents of TTIP, the models of both the EU and US economies must look to 
converge for efficiency gains to be realised3. The treaty’s detractors hold that such 
convergence will err towards the free market in its framing and will thus weaken 
regulation4. 
 
There is a parallel discussion that focuses on how the economy and economic 
development impacts on health. The term ‘health policy space’ is often used to 
describe the juncture where economic theory and practice meets public health policy 
and practice. This returns as a continuing theme in FTAs with the healthcare sector 
often categorised in a manner so as to exclude it from the full provisions of a FTA, on 
the basis that health is unique in that it focuses on underpinning a fundamental right 
and/or that market failure is both more likely and more problematic than other areas of 
economic activity. 
                                                             
2 See, for example, chapter 5 of JS Mill’s ‘On Liberty’ (1859). 
3 http://trade.ec.europa.eu/doclib/docs/2013/september/tradoc_151787.pdf 
4http://www.portugal.gov.pt/media/1283558/Prospects%20for%20regulatory%20convergence%20under%20TTIP%20%
28English%29.pdf 
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3.2 Public Health Law 
On the grounds of being able to protect public health, the legal basis for the state’s 
intervention in the market is historically well established. With roots in common law 
there has been a clear and long-standing link between infection control and regulation. 
Understanding this historical context helps to make sense of the movement from 
regulation of infection control to that of non-communicable diseases. 
 
Current developments in international public health law can be traced back to a 
European movement to bring together infection control practice with the right to health 
as part of the post Second World War settlement5. Writers such as Taylor and Bettcher 
assert that international cooperation in public health matters should be viewed as being 
“a fluid process, ranging from non-binding instruments, such as recommendations, 
guidelines, resolutions and declarations to binding ones such as treaties”6.  
 
The World Health Organisation (WHO) Constitution, Article 55 of the United Nations 
(UN) Charter and the International Covenant on Economic, Social and Cultural Rights 
(ICESCR) provide a basis for action. It has seen the WHO move from developing non-
binding instruments to instruments of a more binding nature such as the Framework 
Convention on Tobacco Control (FCTC). 
 
The principles of international trade, as recently set down by bodies such as the World 
Trade Organisation (WTO), are increasingly relevant to public health law. Whilst FTAs 
such as the North Atlantic Free Trade Agreement (NAFTA) and the Canada Europe 
Trade Agreement (CETA) allude to the idea of sustainability within their preamble or 
objectives, there is limited specific mention of the promotion of health or societal well-
being. As a consequence some health policy issues such as access to medicines or 
tobacco control are challenged by the terms of trade law.  
 
Writers such as Wallerstein talk about how globalisation has modified the manner in 
which power is distributed amongst states and how regulatory power is exercised7. This 
constitutes a paradigm shift, although the extent to which citizens are fully aware of 
how the potential shift of powers away from nation states or from them as citizens is 
less certain.  
 
Equally when considered at an aggregate level, as writers such as Valdi has done, 
then it is possible to see how trade and health goals can align or even reinforce each 
other. However when one examines the issue at a more granular level, it is apparent 
that not only are there significant areas of potential conflict, but that such conflict could 
in fact generate fundamental discord. When asked about the ability of an FTA such as 
TTIP to be mutually compatible in supporting the aims of trade and public health 
Professor Robert Stumberg at Georgetown University commented that, whilst “it may 
look like a ‘win-win’ from an orbit of 60,000 feet, this is far less the case when viewed 
from 60 feet”8.  
                                                             
5 Vadi P 26-27 
6 Taylor, A and Bettcher, D (2002) in Valdi p. 33 
7 I. Quoted in Vadi (2013) page 47 
8 Interview with Professor Robert Stumberg 
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3.3 The Era of Multilateralism: from GATT to the WTO 
Multilateral trade treaties came into prominence in the post-war period with their roots 
in the experience of widespread protectionism during the interwar years. The Wall 
Street crash led to the Smoot-Hawley Act of 1930, which raised US import tariffs by an 
average of 20%. According to Madsen, reciprocal tariff walls were raised and non-tariff 
barriers imposed, so that world trade declined by about a third in the period 1929-
19329. As Anderson and Norheim find, by the onset of the Second World War, world 
trade had fallen to 70% of its 1928 level10. It is widely acknowledged that protectionism 
had proved to be a major factor in prolonging and deepening the Great Depression. 
 
The post-war period ushered in a set of world governance institutions based on the 
experience of the interwar years. In 1947, the General Agreement on Tariffs and Trade 
(GATT) was signed by 23 countries to address the danger of protectionism and 
promote global prosperity. GATT introduced a forum for on-going negotiations for 
promoting free trade based on the most favoured nation (MFN) and non-discrimination 
principles11. It also enacted a ratchet mechanism to prevent any return into 
protectionism once tariff rates have been agreed on (apart from built-in ‘safeguard’ 
clauses).  Each round of talks brought down tariffs. According to the Economist, GATT 
has reduced tariffs from an average of 40% to 4% in participatory countries, and has 
accompanied a 16-fold rise in global trade12. 
 
GATT has always been central to Europe-US trade relations, and a brief history puts 
the size of TTIP into perspective. The Kennedy round, which saw highly significant tariff 
reductions (a 35% cut, on average), was a response to the establishment of the 
common European market in 1958. These cuts were across the board, with 
exemptions made only for sensitive sectors. The subsequent Tokyo round began the 
trend of addressing non-tariff barriers to trade, as well as cutting tariffs by a third again. 
The Uruguay round in 1986 introduced the WTO as a platform for negotiating, 
administering and implementing FTAs.  
 
The Uruguay round was also important as it also saw the first steps on extending the 
principle of non-discrimination to new areas of international commerce: the General 
Agreement in the Trade in Services (GATS), the Agreements on Technical Barriers to 
Trade (TBT), Sanitary and Phytosanitary Measures (SPS), Government Procurement 
(AGP), and Trade-Related Aspects of Intellectual Property Rights (TRIPS) and of 
Investment Measures (TRIMS). These advancements of liberalisation into new sectors 
set the tone for the next two decades. NAFTA (1994) was the first FTA to bring the 
spirit of the Uruguay round into considerable force. The failure of the Doha round 
marked the decline of multilateralism and the rise of regionalism. 
 
                                                             
9 Madsen, Jakob B. "Trade barriers and the collapse of world trade during the Great Depression." Southern Economic 
Journal (2001): 848-868. 
10Anderson, K. and H. Norheim (1993), ‘Is World Trade Becoming More Regionalized?’, Review of International 
Economics, Blackwell Publishing, vol. 1(2), pages 91-109, June. 
11 The MFN (most favoured nation) clause in automatically extends the lowest tariffs negotiated with one country to all 
other countries. However, Article 24 of GATT permits countries to make an exception in the case of FTAs and customs 
unions. 
An example of non-discrimination is the National Treatment clause, which commits governments to treating domestic 
and foreign products with the same regulatory standards. 
12 “Survey of world trade: Time for another round”, The Economist, Oct 1st 1998 
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Dates Trade Agreement Event Developments 
1947 GATT established 23 member countries. Tariff reduction by 
about 20 %. 
1949-61 Four GATT rounds 18 new member countries. Tariff reduction 
by around 3% in each round. 
1958 European Common Market 
established 
Near-comprehensive tariff eliminations in the 
six member countries. 
1964-67 GATT Kennedy round Tariff reduction by about 35 %. 
1973-79 GATT Tokyo round Tariff reduction by about 33 %. Introduction 
of non-tariff measures. 
1986-94 GATT Uruguay round WTO, GATS, TRIMS, and TRIPS 
established. 
1994 NAFTA established Regional FTA era. 
Near-comprehensive tariff eliminations.  
Entrenchment of Uruguay-round agenda. 
2001- GATT Doha round (stalled) 
 
2004 AUSFTA, US-Chile FTA 
established 
 
2011-12 KOREU, KORUS established 
 
2014 CETA, TTIP, TTP, TISA in 
various stages of completion 
 
Figure 1 Timeline of Significant FTAs  
3.4 General Agreement in the Trade in Services (GATS) and the 
Trade in Services Agreement (TISA) 
Perhaps because of the sensitive nature of liberalising trade in services, GATS was 
negotiated outside of the rigorous GATT framework. The agreement was plurilateral 
(voluntary) for GATT members and, significantly, did not require reciprocity in 
liberalisation; it gave a large degree of autonomy to signatory states as to the level of 
liberalisation to which they could commit. GATS precluded any significant standardised 
agreements on essential matters such as repatriation of capital and tax treatment. 
According to Thornberg and Frances13, this meant that countries only liberalised 
service imports in sectors in which they had a comparative advantage, retaining 
protection in their relatively inefficient sectors, thereby rendering the whole exercise 
redundant from the point of view of free trade. 
 
Health is one of the sectors with the fewest signatories in GATS. This is because, as 
many commentators emphasise14, liberalisation in a health market may significantly 
distort the ability to provide services to all income groups.  For example, the 
liberalisation of health insurance may result in insurers cutting services to the poorest. 
Similarly, liberalising hospitals may attract the most qualified staff to the private sector, 
leaving the basic public system with less well qualified staff, in what the WTO 
                                                             
13 Thornberg, Christopher F., and Frances L. Edwards. "Failure of Trade Liberalization: A Study of the GATS 
Negotiation." J. Int'l Bus. & L. 10 (2011): 325., 
http://scholarlycommons.law.hofstra.edu/cgi/viewcontent.cgi?article=1172&context=jibl 
14see, for example, Mackintosh et al. (2005), ‘Commercialization of health care: global and local dynamics and policy 
responses’ 
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Secretariat termed “cream skimming”15. In the international context, trade in services 
may lead to ‘brain drain’ and severe shortages of professionals in developing countries. 
 
TISA is currently in negotiation and can be considered “GATS plus”. One commentator 
in the evidence review claims that although it is taking place outside of the WTO 
framework, the intention being to bring TISA in line with GATS at a later date16. Of 
particular relevance to this study, other commentators in the literature frame TISA as a 
broader and shallower agreement on trade in services designed to accompany TTIP’s 
(more profound) services chapter17. 
 
TISA is being negotiated by the so-called “Really Good Friends of Services” group, 23 
liberalised countries, which broadly span the TTIP and TPP membership. The 
prospective agreement is typical of the new wave of regional FTAs in that it is a 
negative-list treaty with a standstill and ratchet clauses to lock in current and future 
privatisations. It is likely that TISA will be a reciprocal treaty, to avoid the failure of 
GATS. 
 
Talks are in secret and, according to a paper leaked on Wikileaks; the TISA draft is 
classified until five years after the TISA is implemented18. The paper shows that the 
focus so far has been on the potential impacts on financial services, but other 
stakeholder groups are already expressing fears over its effects on public health 
provision19. According to one such group, TISA may lead to irreversible privatisation; 
restrictions on health and safety regulations, as well as environmental and consumer 
protection regulations; restrictions on the licencing and accreditation of public 
services20. 
3.5 Further International Trade Treaties 
Further treaties have been agreed in relation to Technical Barriers to Trade (TBT), 
Sanitary and Phytosanitary Measures (SPS), Government Procurement (AGP), and 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) and of Investment 
Measures (TRIMS). Any country wishing access to the trade treaties encompassed by 
WTO membership is obliged to adhere to these accompanying treaties (except AGP). 
 
UNCTAD, the United Nations Conference on Trade and Development, states that 
TRIMS are rules that specify WTO provisions on “national treatment”: they ban any 
discrimination against foreign products. In practice, although it is contested that TRIMS 
has been used to impose certain “performance requirements”21 on foreign investment. 
                                                             
15 ‘Health and Social Services-Background Note by the Secretariat’, Council for Trade in Services, WTO 
[S/C/W50]- 18/09/98. 
16https://www.policyalternatives.ca/sites/default/files/uploads/publications/National%20Office/2014/04/TISA_Versus_Pu
blic_Services.pdf 
17 http://mddb.apec.org/Documents/2013/SOM/SOM-ABAC-PECC-DIA/13_som-abac-pecc_dia_002.pdf, and 
http://www10.iadb.org/intal/intalcdi/PE/2013/12580.pdf 
18 https://wikileaks.org/tisa-financial/press.html 
19 https://wikileaks.org/tisa-financial/Analysis-of-secret-tisa-financial-annex.pdf 
20 http://ourworldisnotforsale.org/en/signon/international-civil-society-sends-letter-governments-opposing-proposed-
trade-services-agreeme 
21 See p.2 of the 2003 UNCTAD report on Performance Requirements for a detailed explanation 
http://unctad.org/en/docs/iteiia20037_en.pdf 
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Evidence in the literature review found that while this is ostensibly to fight corruption, 
negative repercussions might also be incurred by diminishing the ability of 
governments to promote extra-commercial, such as environmental or labour, standards 
in investment22. 
 
The central provision in the text of the TRIPS agreement is a minimum copyright and 
patent term of 20 years23 (although some LDCs have impact delays of 10 or 20 years). 
This provision faced challenge by developing countries over the likely price effect on 
generics, especially with regards to HIV antiretrovirals, which eventually led to the 
Doha Declaration in 2001. This indicated that TRIPS should be suspended for the 
relevant medicines required to protect public health, and gave flexibility to the 
implementation of IP rights. However, a report by the World Health Organisation in 
2011 found that most developing countries had not incorporated the Doha flexibilities 
into their IP law, owing to lack of information and legal resources, as well as 
complications thrown up by parallel investment treaties24 
 
The Agreement on Technical Barriers to Trade (TBT) (meaning domestic regulations 
unrelated to tariffs) allows domestic regulations to set standards that are higher than 
agreed trading standards if they can be justified on environmental or public health 
grounds. It is of note that France used TBT successfully in 2001 to defend its ban of 
asbestos imports, after being challenged by Canada. Proponents of TTIP argue that 
given that the TTIP is aligned to these TBT provisions, there would appear to be scope 
for national standards to be set at a higher than the prevailing level as long as this can 
be justified on such grounds25. 
 
The Agreement on the Application of Sanitary and Phytosanitary Measures (SPS) has, 
in the evidence review, been shown to weaken the precautionary principle by 
mandating a scientific risk assessment on all regulatory standards. It allowed Canada 
and the US to impose sanctions to the value of $150m on the EU in 1998, in retaliation 
for the EU’s long-held ban on hormone-treated beef imports, as there was insufficient 
scientific evidence to support the ban. This matter has been subsequently resolved by 
facilitating increased quotas for non-hormone treated US and Canadian beef26. 
 
The Agreement on Government Procurement (AGP), which is plurilateral, requires 
governments to take social policy objectives into account when selecting between 
tenders. There are questions raised in the literature review over the desirability of 
empowering extra-commercial objectives, as these may be used to disguise political 
agendas27. 
                                                             
22Salzman, (2000) ‘Labor rights, globalization and institutions: the role and influence of the Organization for Economic 
Cooperation and Development’ 
23 See articles 9 and 33 of the TRIPS agreement, http://www.wto.org/english/tratop_e/trips_e/t_agm0_e.htm 
24http://apps.who.int/medicinedocs/documents/s21425en/s21425en.pdf 
25 http://www.kommers.se/Documents/dokumentarkiv/publikationer/2014/TTIP-snabbrapport-eng.pdf 
26 p.100, ‘The Transatlantic Collasus’, 
http://www.collaboratory.de/images/archive/8/8d/20140116221236!TheTransatlanticColossus.pdf#page=100 
27 http://www.unpcdc.org/media/132243/ox.pdf 
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3.6 Effectiveness of WTO agreements and the public health 
exemptions 
With the exception of AGP, these programmes along with GATT are the mandatory 
and founding agreements of the WTO, so the majority of countries are party to them. 
They are enforced by a country-to-country dispute settlement mechanism. Hence, their 
use may be shown by the rise in international trade disputes facilitated by the WTO as 
compared with GATT previously, from an average of three per year with GATT to 25 
cases per year with the WTO28.  
 
The WTO agreements prohibit policies that are demonstrated to be purely protectionist. 
Those of a purely public health motivation are likely to be upheld by the TBT or SPS 
agreement, and to a lesser extent by the Doha declaration. However, the vast majority 
of cases have fallen in between the categories, and the tendency of arbiters in this 
situation has consistently been to claim the policy in question illegal on the basis of 
protectionist intention. This is of concern as it is not always possible to separate 
protectionism from public health concerns.  
 
There have been complaints in the literature that the health exemption provisions are 
too complex or costly for implementation, making for “regulatory snare” in some cases. 
In other cases, “regulatory chill” has come into play (whereby policy makers reduce 
policy space in the erroneous belief that certain policies are illegal).  
3.7 Bilateral investment treaties in the European Union  
The European Union is the most developed example of a regional FTA, and thus has a 
host of legal frameworks that also impact on the ability of governments to act in the 
area of public health. Beyond the fundamental legal framework allowing the free 
movement of capital, labour, goods and services, discrimination is prohibited in areas 
such as government procurement and investment. 
 
EU regulatory law has considerable reach over product safety, labelling and marketing. 
For example, it includes directives that prohibit the direct-to-consumer advertising of 
prescription-only pharmaceuticals, and the advertising of tobacco on television29.  
 
Bilateral investment treaties (BITs) became common between Western Europe and 
Central and Eastern Europe during the 1990s. They give increased protection to 
foreign investors. The accession of the 12 new member states in the 2000s brought 
these BITs alongside EU law; currently, there are an estimated 190 intra-EU BITs, out 
of the 1500 EU-based BITs. Altogether, countries in Central and Eastern Europe have 
been sued at least 77 times whereas there have only been seven cases in Western 
Europe30. 
 
The Lisbon Treaty that was has provided additional new powers for the EU to directly 
negotiate Foreign and Domestic Investment (FDI) treaties and has additionally 
                                                             
28 http://www.wto.org/english/res_e/booksp_e/historywto_07_e.pdf 
29  Directives 2001/83/EC and 89/552/EEC, respectively 
30 http://www.tni.org/sites/www.tni.org/files/download/briefing_on_intra-eu_bits_0.pdf 
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provided that the European Parliament must approve FTAs to be ratified31. CETA and 
TTIP represent two significant new FTAs being negotiated following the signing of the 
Lisbon Treaty. 
3.8 International Health Law 
The World Health Organisation (WHO) is another post-war institution established to aid 
global governance. Its role is to provide leadership on public health matters. Its 
relevance to international trade is in the setting of prudent norms and standards, the 
basis of which is article 25 of the Universal Declaration of Human Rights.32 WHO sets 
out its trade agenda as follows: 
 
“WHO works to achieve greater policy coherence between trade and health 
policy so that international trade and trade rules maximize health benefits and 
minimize health risks, especially for poor and vulnerable populations.”33 
 
The aim of WHO, and international health law generally, is to help support the provision 
of health policy space. 
 
An example of this aim being realised is the 2003 WHO Framework Convention on 
Tobacco Control (FCTC). FCTC sets out minimum standards governing the production, 
distribution, marketing and taxation of tobacco under a progressive agenda. It has been 
ratified in 179 countries, including all EU states but not the US.34 A report in 2010 noted 
that the treaty had made considerable impact, with the vast majority of parties 
implementing remedies such as tobacco education programmes, large health warnings 
on packaging and advertising bans.35 
 
The FCTC is the first of its kind – a multilateral, binding agreement setting minimum 
regulation standards regarding non-communicable disease. Agreements on other 
issues such as childhood obesity are currently subject to discussion. According to 
WHO, the number of obese children under five will come close to doubling in the period 
2012-2025 if current trends continue.36 A WHO commission was recently set up to 
address the problem, and identified several areas of concern including the advertising 
of unhealthy foods aimed at children. 
3.9 Summary Assessment 
The alignment between public health goals and trade liberalisation goals has not 
always been clear. Initiatives such as the FCTC have demonstrated the potential of 
international law to address issues relating to NCDs. The current WHO campaign on 
childhood obesity is likely to be pivotal, most particularly where it moves from education 
to regulation. How well placed international governance structures are to mediate a 
                                                             
31 http://trade.ec.europa.eu/doclib/docs/2011/june/tradoc_147977.pdf 
32 “Everyone has the right to a standard of living adequate for the health and well-being of himself and of his family, 
including food, clothing, housing and medical care and necessary social services….” 
33 http://www.who.int/trade/trade_and_health/en/ 
34 http://www.who.int/fctc/signatories_parties/en/ 
35 http://www.who.int/bulletin/volumes/88/2/10-075895/en/ 
36 http://www.who.int/dietphysicalactivity/end-childhood-obesity/en/ (from 40m in 2012 to 70min 2025) 
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process of engagement between public and business interests will be instrumental in 
determining the extent to which international trade and health law can be aligned. 
These issues have a significant impact on agreements such as TTIP as they can 
underpin or provide challenge to them, an issue that is returned to in the final sections 
of this report. 
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4.0 Economic Impact 
The overall potential economic benefits of TTIP are largely projected to come from non-
tariff based reform. Projected benefits have been subject to empirical challenge, and 
reference to other FTAs indicates impact is difficult to assess and that all projections 
should be treated with caution.  
 
The development of TTIP has been structured in three parts, each of which broadly 
accord with the themes considered in the previous chapter on FTAs. 
1) Market Access, which focuses on removing custom duties on goods and 
restrictions on services, gaining better access to public markets, and making it 
easier for foreign investment. Themes include: 
§ Goods, including market access and rules of origin; and 
§ Services and Investment, ranging from regulation of financial services to ISDS. 
2) Industry-specific regulation: which aims at delivering regulatory coherence and 
cooperation, and is focussed on eliminating or reducing regulatory barriers such as 
bureaucratic duplication of effort. Chapters include:  
§ Horizontal chapters: such as regulatory coherence and technical barriers to 
trade; and 
§ Specific sectoral agreements: including pharmaceuticals and medical devices. 
3) Broader rules and principles and modes of co-operation which focus on improving 
cooperation in relation to international standards, with chapters on: 
§ Public procurement;  
§ Intellectual property; and  
§ Competition policy including treatment of state owned companies. 
4.1 Economic Impact 
At the heart of free trade liberalisation is the normative belief that such reform will have 
a positive economic benefit. The European Commission as part of the development 
process has commissioned a number of economic studies which support this belief. 
The Centre for Economic Policy Research (CEPR) study for instance predicts that an 
ambitious TTIP deal would increase the size of the EU economy by around €120 billion 
(or 0.5% of GDP) and the US by €95 billion (or 0.4% of GDP)3738. This would be a 
permanent increase in the amount of wealth that the European and American 
economies can produce every year. The CEPR study uses a computable general 
equilibrium (or CGE) model to simulate the impact of TTIP. These are standard tools 
for trade economists that create a computerised simulation of the world economy and 
model what happens when changes are introduced.  
 
Providing a broader framework for assessing benefits realisation has proved to be 
more challenging. To take the example of NAFTA as the most significant multilateral 
FTA to be negotiated by the United States, it is apparent that there has been significant 
disagreement regarding the extent to which there have been manifest benefits accrued 
                                                             
37 http://trade.ec.europa.eu/doclib/docs/2013/march/tradoc_150737.pdf 
38 http://trade.ec.europa.eu/doclib/docs/2013/september/tradoc_151787.pdf 
 27 
 
as a result of its implementation, what harms have been caused and the dynamics of 
these as well as any overall cost benefit assessment.  
 
A March 2014 report commissioned and financed by the Confederal Group of the 
European United Left/Nordic Green Left (GUE/NGL) political group in the European 
Parliament published by ÖFSE (Austrian Foundation for Development Research) 
examined a range of studies that have been commissioned to consider the potential 
impact of TTIP, including Ecorys (2009), CEPR (2013), CEPII (2013) and 
Bertelsmann/ifo (2013). The ÖFSE study broadly confirm growth projections although it 
argues that the 80% of total TTIP benefits to be ‘overly optimistic’39. The report also 
contends that projected gains in terms of increased exports could be matched or 
exceeded by the impact of revenue losses and direct and indirect costs resulting from 
short term growth in unemployment. Of particular relevance to the public health debate 
the report also challenges the estimated gains due to the removal of non-tariff barriers 
(NTBs).  
 
The fundamental challenge in seeking to validate these estimates is that they are 
based not on comparative data drawn from the realised benefits achieved by existing 
FTAs, but on the basis of a simulation exercise. CGE models have been subject to 
significant challenge, not least from civil society organisations. Whilst it is not within the 
remit of this study to consider in depth the challenges to CGE modelling, it is important 
to highlight the fundamental challenges of such an approach and most particularly their 
dependence on the veracity of the assumptions that underpin them. As a 2006 Oxfam 
funded study comments: 
 
“CGE models can be useful quantitative supplements to experimental thinking about 
the importance of different potential causal linkages among economic variables at the 
country or world level. However, mechanically churning out ‘projections’ of welfare 
gains or any other indicator subject to one single set of causal assumptions and 
parameter values is a fundamental misuse of a sometimes helpful tool.”40 
 
In general the economic assessments have generally drawn conclusions that aligned to 
the aims of their sponsoring bodies. Fully independent studies have been more difficult 
to identity. However a Global Development and Environment Institute Working Paper 
from October 2014 by Jeronim Capaldo at Tufts University presents a negative 
assessment of the potential economic impact of the TTIP41. Using the United Nations 
Global Policy Model, which incorporates different assumptions on macroeconomic 
adjustment, employment dynamics, and global trade to CGE modes, the study 
concludes that TTIP would lead to a contraction of GDP, personal incomes and 
employment. The study also projects an increase in financial instability and a 
continuing downward trend in the labour share of GDP. 
4.2 Employment, Wages & Productivity 
Not only do the CGE-based studies identify overall economic benefits as being likely to 
accrue from TTIP, but they also identify direct benefits in terms of increased 
employment, wages and productivity. A study commissioned by the Bertelsmann 
                                                             
39 http://guengl.eu/uploads/plenary-focus-pdf/ASSESS_TTIP.pdf 
40 Modelling the Impact of Trade Liberalisation, Oxfam International Research Report, July 2006 
41 http://www.ase.tufts.edu/gdae/Pubs/wp/14-03CapaldoTTIP.pdf 
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Foundation, an organisation which is broadly supportive of TTIP contends that for 
Germany alone: 
 
“A TTIP would benefit the entire (German) economy. Many new jobs would be 
created in the manufacturing industry, especially in the electronics industry and 
metal processing. Non-export oriented industries in the service sector would 
also benefit indirectly from an agreement through inter- and intra-sector 
relationships.”42 
 
It is of note that the report also states that “because of the relatively high sector-specific 
impact, low-skilled individuals would also be subjected to more changes than medium 
or highly qualified”43. However it should be noted that the Bertelsmann Foundation is a 
private operating foundation committed to the view that competition and civic 
engagement are essential for social progress. 
 
A particularly informative debate in the UK House of Lords Select Committee in May 
2014 highlighted the views of a range of stakeholder groups. It was evident from these 
that trade unions have differing views on the potential impact of TTIP. Whilst there was 
recognition of the potential positive impact on jobs, concern was expressed about the 
potential movement of jobs to the US, although other experts cited the relatively higher 
wage levels in the U.S. as being one reason that such movement would be unlikely. 
 
A University of Toronto Canadian Institute for Advanced Research (CIAR) and National 
Bureau of Economic Research (NBER) report on the Canada-US FTA by Daniel Trefler 
began to identify short and long term trends that related to both employment and 
productivity44. The findings are that where there are tariff reductions, then there is an 
impact on productivity in that it increases as less productive capacity is reduced. 
However, the report also found that the impact on employment is more problematic to 
determine, and that employment levels can fall as well as increase as a result of their 
introduction. 
 
It is also important to differentiate between FTAs and the underlying economic position 
of contributing countries. With this in mind the traditional view is of FTAs between 
MDCs and LDCs is that under an FTA the latter lose employment to the former. A 
regularly voiced stakeholder view from the US regarding NATFA is that it had 
significant and negative impact on employment and wage levels. However, the Council 
on Foreign Relations (CFR, an independent, nonpartisan think tank that receives 
significant corporate financial support, reports that many economists agree NAFTA has 
caused some overall improvement in U.S. jobs, but at the cost of short term 
fluctuations that have impacted on employment levels. 
 
Studies that have focussed not just on MDC to MDC FTAs but to those involving the 
US and EU suggest a more benign impact on employment. A further European 
Commission funded study undertaken by the Ecorys consultancy stated that real 
wages follow the same pattern as national income, resulting in the highest real wage 
                                                             
42 Bertelsmann Stiftung Future Social Market Economy Policy Brief May 2013 
43 op cit 
44 D Trefler (2006) The Long and Short of the Canada-U.S. Free Trade Agreement University of Toronto Canadian Institute for 
Advanced Research (CIAR) and National Bureau of Economic Research (NBER) 
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increases under the EU-US FTA. The same study also found that developments in real 
wages are similar for unskilled and skilled labour45. 
4.3 Impact on Less Developed Countries 
A report by CARIS, University of Sussex for the Department for International 
Development on the potential impact of TTIP on LDCs highlighted some areas of risk 
particularly in relation to trade between LDCs and the EU, but drew the overall 
conclusion that key sectors for such countries such as textiles were unlikely to be 
substantially impacted by TTIP46. Other reports such as that by ÖFSE do highlight 
other potential areas of concern for developing countries but the overall potential 
impact in relation to trade should be assessed as meaningful but not highly impactful. 
What has been noted by the CARIS study is that LDCs have not been included within 
the decision making process and as such have not been able to make the case for 
alignment in respect of issues such as standards and testing of goods and produce. 
4.4 Summary Assessment 
The principal area of economic benefit from TTIP to the EU is predicted to emanate 
from non-tariff based regulatory reform. At around €120bn the magnitude of impact is 
not insignificant although the strength of recent empirically based challenges should 
not be underestimated. Equally, to help locate the discussion within the public health 
realm one can cite a 2012 Centre for Addition and Mental Health report by Jürgen 
Rehm and Kevin Shield that states that the social costs of alcohol consumption for the 
year 2010 could amount to €155.8 billion47. Whilst the study does not directly consider 
the impact of regulatory public health intervention in this field, it is evident that the value 
magnitude of just one public health issue bears comparison with the potential direct 
economic gains that are projected to accrue from TTIP. 
  
                                                             
45 ECORYS 2009 The impact of Free Trade Agreements in the OECD 
46 
http://tradesift.com/Reports/Potential%20Effects%20of%20the%20Proposed%20Transatlantic%20Trade%20and%20Investm
ent%20Partnership%20on%20Selected%20Developing%20Countries_DFID_Final%20Report_July2013.pdf 
47 http://amphoraproject.net/w2box/data/AMPHORA%20Reports/CAMH_Alcohol_Report_Europe_2012.pdf 
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5.0 Health Impact 
Health Impact will be felt across goods and services, in food, pharmaceuticals and the 
delivery of health services. Few defined benefits could be identified. Identified 
disbenefits were also limited, although the scale and impact of these is likely to be 
dependant on a highly complex interplay of factors. 
 
For presentational purposes this report considers these issues on a thematic basis 
covering those issues that evidence suggests could have greatest impact within the 
health domain: 
 
§ Trade in goods 
§ Technical barriers to trade (TBT) 
§ Sanitary and Phytosanitary (SPS) Issues 
§ Trade in Services 
§ Dispute Resolution; and  
§ Intellectual Property 
5.1 Trade in Goods 
The EU and US already have one of the lowest levels of tariffs, and relative to other 
FTAs tariff reduction cannot be said to be the dominant part of TTIP, as it represents 
only 20% of the overall projected value to be realised from its implementation.  
 
TTIP is anticipated to increase US investment into the European Union and as a 
consequence could lead to reduced consumer prices and increase choice. Generally 
FTAs involve zero tariffs for foods although there are transition periods such as the 
seven-year period for grain provided for in CETA. Where particular issues cannot be 
resolved then FTAs may agree to put issues into the ‘long grass. One such as example 
of this is the US-Australia FTA that includes provision to review labelling of GM in the 
future48. 
 
5.1.1 Agri-Food 
Health will be impacted by tariff reductions as processed foods would account for the 
single largest increase in import of goods by sector (2.37%), which may in turn impact 
on reducing the price of unhealthy foods within the EU, thereby affecting diet and 
health.  
  
The European Union is the world’s leading processed food exporter, with roughly twice 
the exports of the United States. EU exports of processed food products reached $91 
billion in 2012, growing 28% over five years49. As such the EU remains the larger 
exporter of processed foods, but following the overall logic of FTAs one would expect a 
reduction in tariffs to result in an increase in trade and a reduction in prices. Were this 
to happen in the EU, a significant proportion of such products would likely be high in 
sugar, salt and saturated fats. Given that there is already a good deal of focus being 
                                                             
48 http://www.bilaterals.org/?australia-us-free-trade-agreement 
49 http://www.fas.usda.gov/data/us-processed-food-exports-growth-outlook 
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put onto the issue of unhealthy foods by the public health community, one can see that 
TTIP could have the impact of exacerbating the situation by facilitating a reduction in 
the market price for such goods and thereby an increase in uptake and consumption. 
 
A number of studies have sought to establish the relationship between price and 
demand for unhealthy food, with many reporting a significant effect50. For example, in a 
paper for PLOS Medicine (an open-access medical journal), David Stuckler and 
colleagues have established a correlation between US FTAs and an increase in some 
unhealthy foods (soft drinks) in LDCs51. On this basis, it would be possible to establish 
an overall potential effect for TTIP in relation to a reduction in the price of unhealthy 
foods, although no such study has been undertaken to date. The overall impact of 
increased market access on public health is therefore more difficult to establish.  
 
The same issue could apply to alcohol, where there is again an expectation of reduced 
tariffs and increased imports. As a reference the CETA agreement will eliminate all 
import tariffs on spirit alcohols and wines. Indeed, both industry groups Spirits Canada 
and Spirits Europe see the potential for growth in Europe and Canada respectively. 
Spirits Canada have said that they expect to double their exports to Europe, targeting 
in particular Eastern Europe. Whilst the position regarding tariffs on alcohol between 
the US and Europe are different, TTIP clearly represents a potential challenge to 
alcohol control policies if its implementation results in reductions in price and increase 
in supply.  
 
If this is the case, then public health bodies may seek to use a number of regulatory 
instruments to offset any detrimental health impact. Concern has been raised by a 
number of public health stakeholder groups that the TTIP could make such a regulatory 
response more difficult to achieve. This issue is discussed further in the Health Policy 
chapter of this paper. 
5.2 Technical Barriers to Trade 
The OECD defines technical barriers to trade (TBT) to be technical regulations, 
minimum standards and certification systems for health, safety and environmental 
protection and to enhance the availability of information about products, which may 
result in the development of TBTs52. There are a plethora of organisations such as ISO 
that work on producing international standards, but the situation remains that there is 
significant variation in relation to standards and to compliance regimes. The WTO 
addressed this issue at the Uruguay Round of GATT with the development of the TBT 
Agreement.  
 
The TBT Agreement that came into force in 1995 is binding on all WTO members and 
the focus more recently has been to draw upon the principles and guidelines when 
developing FTAs such as TTIP. The two most important principles underlying these 
negotiations relate to standards and compliance, and the interpretation of both could 
have a marked impact on public health. 
 
                                                             
50 D, Talukdar & C, Lindsey (2013) To Buy or Not to Buy: Consumers' Demand Response Patterns for Healthy Versus Unhealthy 
Food Journal of Marketing: March 2013, Vol. 77, No. 2, pp. 124-138 
51 http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001235#pmed.1001235.s007 
52 http://stats.oecd.org/glossary/detail.asp?ID=2683 
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In an initial discussion document circulated by the European Commission, a basic 
framework for TBT negotiations in TTIP has been set out. The documents states at an 
early juncture that: 
 
“First, as far as possible, measures should aim at removal of unnecessary 
barriers to trade arising from differences in the content and application of 
technical regulations, standards and conformity assessment procedures.53”  
 
A position paper by CEN (European Committee for Standardisation) and CENELEC 
(European Committee for Electrotechnical Standardisation) is supportive of TTIP and 
its TBT provisions, but it does note that “…not only the interpretation of “convergence 
to international standard” is different on both sides of the Atlantic, but also the 
understanding of “transparency and predictability of regulatory and standards setting 
processes”54. 
 
A 2013 paper by the Center for International Environmental Law, which declares its 
aims to be to promote human health and ensure a just and sustainable society, sets 
out four concerns relating to regulatory convergence. It contended that TTIP could 
restrain the continued development of stronger laws in the EU and that it may pre-empt 
stronger sub-regional laws by Member States. The paper also contends that TTIP 
could weaken developing standards for human health, labour and the environment in 
both the EU and US, such as those relating to nanomaterials and endocrine disruptors. 
It could also influence the development of regulations and standards outside the EU 
and US, including countries with economies in transition that have recently adopted 
environmental policies more similar to European than American approaches55.  
 
The early rounds of TTIP negotiations resulted in a European Union proposal to 
establish a joint EU-US oversight body for the development of regulations in the two 
regions. This “Regulatory Cooperation Council” would consist of the heads of the most 
important EU and US regulatory agencies, monitor the implementation of commitments 
made, and consider new priorities for regulatory cooperation. This appears to suggest 
that there would be an on-going commitment towards regulatory cooperation, not least 
given the proportionate value attached to regulatory over tariff reforms in TTIP. 
5.2.1 Pharmaceuticals 
The treatment of pharmaceuticals within the TBT chapter of TTIP is of particular 
importance from a health perspective, with proponents believing that it will elicit 
significant benefit but critics believing that it could have a detrimental impact not least 
with respect to medicines’ affordability. As Leigh Hancher has contended in a 2010-
edited book on Health Systems Governance in Europe, “the twin tracks of ‘regulatory’ 
and ‘market’ pathways are intersecting in new and challenging ways for the major 
stakeholders in the European Union”56. 
 
                                                             
53 EU - US TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP Technical barriers to trade Initial EU position paper 
(http://trade.ec.europa.eu/doclib/docs/2013/july/tradoc_151627.pdf) 
54 CEN – European Committee for Standardization and CENELEC – European Committee for Electrotechnical Standardization 
Position Paper on EU-US Transatlantic Trade and Investment Partnership (TTIP) – Technical Barriers to Trade – Initial EU 
Position Paper 
55 Center for International Environmental Law (2013) Trans-Atlantic Trade and Investment Partnership (TTIP) Monitor 
56 http://apps.who.int/medicinedocs/documents/s21372en/s21372en.pdf 
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Pharmaceuticals represent an important industry sector for US and EU policy 
negotiators, with those in Europe in particular seeking to address a range of pressing 
market and public health related issues: 
 
“Europe’s industry, rightly or wrongly, is hence perceived by the sector, as well 
as policy-makers at the European level, to be facing serious challenges, 
matched only by those facing public health, challenges driven by demographic 
change and the high cost of innovative treatments.57” 
 
Despite these challenges, the Economist Intelligence Unit anticipates that by 2016 the 
developed European pharmaceutical market will have recovered the sales value lost 
since 2008, and that by 2017 it will have exceed it58.  
 
It is generally acknowledged that most if not all the European Union have to date 
enjoyed relatively good standards of affordable medicines supply, even though levels 
and costs of both generic and branded medicines usage are variable. The mix of public 
and private pharmaceutical purchasing systems and the economic wealth of different 
European Member States means that access to medicines across the EU is by no 
means homogenous.  
 
Since the 1990s pharmaceutical spending as a proportion of GDP has, in line with 
healthcare, generally increased in every European Member State (with the exception of 
Luxembourg)59. The OECD estimates that during the first decade of the current century 
average European spending per capita on pharmaceuticals has risen by almost 50% in 
real terms60. Within the context of the global economic crisis, a range of initiatives have 
been introduced to constrain pharmaceutical costs, including price reductions and 
changes in co-payments, VAT rates on medicines and distribution margins61. Despite 
these initiatives there is evidence that access to medicines in a number of European 
countries remains problematic62. 
 
Pharmaceutical industry associations assert that the TTIP offers significant 
opportunities to reduce regulatory burden, transaction costs and the time it takes to get 
new medicines to market. One assessment of the benefits offered by TTIP that was 
posted on the official blog of Eli Lilly and Company is that it could improve access for 
patients to innovative medicines, support jobs in the European and US pharmaceutical 
industries and be an appropriate benchmark for future trade agreements with other 
countries63. 
 
This illustrative source contends that this would be achieved by means of regulatory 
harmonisation between the European Medicines Agency (EMA) and the Food and 
                                                             
57 http://apps.who.int/medicinedocs/documents/s21372en/s21372en.pdf 
58 https://www2.deloitte.com/content/dam/Deloitte/dk/Documents/life-sciences-health-care/European_austerity.pdf 
59 http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf 
60 http://www.oecd-
ilibrary.org/docserver/download/8110161ec045.pdf?expires=1417430147&id=id&accname=guest&checksum=9C182BC9F71B6C
3A612E2957FB0AF250 
61 http://apps.who.int/medicinedocs/documents/s19046en/s19046en.pdf 
62 http://www.oxfam.org/sites/www.oxfam.org/files/file_attachments/bp-trading-away-access-medicines-290914-en.pdf 
63 http://lillypad.eu 
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Drug Administration (FDA) that would reduce unnecessary duplication and pave the 
way for the development of global standards. Mutual recognition of inspections 
negotiated in TTIP would be based upon the Good Manufacturing Practices (GMP) and 
Good Clinical Practices (GCP) inspections. The current programme of parallel scientific 
advice may also be expanded to cover all medicines, enabling companies to pursue 
applications in both the EU and US and to conduct clinical trials based on a common 
approach. Such an approach finds further support in a joint EFPIA and PhRMA trade 
association position paper on TTIP64. 
 
The European Consumer Organisation (BEUC) also recognised that TBT is likely to 
play an important role and that in the area of harmonisation of GMP and GCP 
procedures, pharmaceutical practices could be improved65. Yet BEUC also expresses 
concerns relating to the expansion of parallel scientific advice within the ‘definition of 
commercial confidentiality’ whereby clinical trials reports could be deemed 
commercially confidential. This could stymie progression towards greater transparency 
of clinical trial data as set out in the new Clinical Trials Directive.  
 
In relation to pricing and reimbursement EFPIA the European pharmacy trade 
association has argued that TTIP should: 
 
“…include a Pharmaceuticals Annex similar to that included in the EU and 
United States’ free trade agreements with Korea to ensure transparent, timely 
and predictable pricing and reimbursement processes that provide applicants 
with meaningful due process.66” 
 
This is one of a number of issues highlighted in a ‘leaked memo’ of priorities for the 
Pharmaceutical industry circulated by the TransAtlantic Consumer Dialogue (TACD). In 
relation to pricing and reimbursement the document states that “when external 
reference pricing, only countries that are similar in terms of their socio-economic level, 
purchasing power, populations, disease burdens and health care system should be 
taken into account; bailout countries while they are undergoing fiscal restructuring 
programmes should be excluded from any referencing.”67   
 
The European generics industry also supports the development of TTIP and has set in 
place its own priorities, which include a regulatory framework allowing single EU/US 
development programmes for generic and biosimilar medicinal products and 
convergence of data requirements for their approval in the EU and the US as well as a 
regulatory framework allowing advanced manufacturing for export purposes68. 
 
The potential for FTAs to materially impact on pharmaceutical prices have also been 
established in other countries such as Australia. A paper written for Globalization and 
Health at the early stage of the Australia-US FTA negotiation process commented on 
the inclusion of a range of similar non-tariff reforms to those being considered in TTIP. 
The paper contends that: 
                                                             
64 http://www.efpia.eu/uploads/documents/EFPIA_PhRMA_TTIP_Online.pdf 
65 http://www.beuc.eu/blog/how-will-ttip-affect-the-health-of-europeans/ 
66 http://www.efpia.eu/uploads/documents/EFPIA_PhRMA_TTIP_Online.pdf 
67 http://tacd-ip.org/archives/1138 
68 http://trade.ec.europa.eu/doclib/docs/2013/june/tradoc_151372.pdf 
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“The potential exists for the AUSFTA to reshape the character of Australia's 
regulatory system concerning medicines from a public good- to a private rights-
oriented system. Should the AUSFTA precipitate such a normative shift 
(particularly one away from scientific cost-effectiveness evaluation of 
pharmaceuticals) the regulatory implications are likely to be profound and 
resonate beyond Australia to impact on the health care sectors of other 
nations69.” 
 
Enhancing the competitiveness of Europe’s pharmaceutical sector remains a strategic 
priority for the European Commission and TTIP provides an important means to help 
achieve this goal. Reconciling this market goal to the regulatory goal of ensuring 
access to medicines for Europe’s 500 million citizens will continue to form an important 
element of the current TTIP negotiations, with on-going attention to the detail under 
consideration required from all interested stakeholder groups. 
 
5.2.2 Agri-Food  
The potential for the TBT chapter to impact on agri-food has been highlighted in the 
literature on the TTIP, although there is far less comment on the subject when 
compared with the issue of food safety. There are examples of how other FTAs have 
impacted on the achievement of broader public health goals such as those related to 
reductions in NCDs and how TBT issues have impacted upon this process.   
 
One relevant comparison from Chile has been highlighted in Nutritional Outlook, a 
resource for the manufacturers of dietary supplements and healthy food and 
beverages70. The paper considers Chile’s new law “Nutritional Composition of Nutrients 
and Their Advertising” as being the first in the world to require label-warning 
statements on foods high in fat, sugar, and salt. The legislation also expands what 
must be listed on nutrition labels including reference to saturated fats, sugars, calories, 
protein, carbohydrates, and sodium content. It is proposed that this will then be 
extended to include nutrient profiles71. Further elements of the proposed policy would 
require some foods to include labels advising consumers to avoid excessive intake of 
certain foodstuffs and would extend to changes in the regulation of food advertising, 
particularly where this currently targets children. 
 
Chile has 59 existing bilateral and regional trade agreements with countries including 
the European Union and the United States. This research study did not find examples 
of action currently being taken under the provisions of these, however during a meeting 
of the World Trade Organization’s (WTO’s) Technical Barriers to Trade (TBT) 
Committee, several member delegations expressed concerns about Chile’s proposed 
food health regulation amendments. Representatives from countries including the 
United States and the European Union contended that such requirements were not 
based on relevant Codex nutrition labelling guidelines and as such that they would 
                                                             
69 Faunce, T. (2005) Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global 
medicines policy 
70 http://www.nutritionaloutlook.com/about 
71 http://www.nutritionaloutlook.com/article/global-regulations-chile’s-new-law-high-fat-sugar-salt-warnings-3-10233 
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create unnecessary barriers to international trade. They also contend that the 
provisions had not been properly brought before the TBT Committee72. 
 
Whilst tax is not a technical barrier to trade the current example of Mexico provides a 
interesting case study in agri-food. In this particular case the NAFTA FTA resulted in a 
significant reduction in tariff levels on soft drinks. Evidence has directly linked the FTA 
to an increase in the consumption of high sugar content drinks and a rise in obesity 
levels73. Yet following significant pressure from public health stakeholder bodies, the 
Mexican Government has recently introduced a tax on such drinks74. The most recent 
evidence suggests that the tax has resulted in a reduction in consumption of around 
10%75.  That having been said the same article confirms that investment levels by US 
soft drink manufacturers continues to grow, with only limited commitments to market 
lower sugar and sugar free alternative products. 
 
Given that over a third of the cases brought to the WTO have involved food76 it is likely 
that this will be an area of particular focus in relation to TTIP, although once again it 
should be stressed that consideration should be viewed within the wider context of 
regulatory provisions provided at an international as well as a regional and national 
level. 
 
5.2.3 Summary Assessment 
Health related TBTs primarily relate to pharmaceuticals and agri-food. The removal of 
TBTs could positively impact on health if pharmaceutical prices fell as a result of 
regulatory efficiencies being realised and innovative medicines getting to the market 
more quickly. Yet such benefits could be offset by concomitant increases in 
pharmaceutical costs resulting from other provisions within the TBT chapter. Equally 
whilst the risk to areas such as agri-food labelling maybe further impacted by 
provisions with the TBT chapter of TTIP, evidence suggests that governments have 
been able to seek to mitigate negative impacts by introducing new public health 
regulation. 
5.3 Sanitary and Phytosanitary (SPS) Measures 
The WTO defines SPS as regulatory measures that seek to protect human or animal 
life from risks arising from additives, contaminants, toxins or disease-causing 
organisms in their food, beverages, feedstuffs; human life, plant as well as animal-
carried diseases, animal or plant life pests, diseases, or disease-causing organisms77. 
From such a perspective SPS related agri-food issues are likely have the greatest 
health consequence.  
 
                                                             
72 op cit. 
73 http://civileats.com/2013/07/17/mexico-public-health-rising-obesity-and-the-nafta-effect/ 
74 http://www.theguardian.com/world/2014/jan/16/mexico-soda-tax-sugar-obesity-health 
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76 Bronkers, M and Soopramanien R (2008) The Impact of WTO Law on European food regulation European Food and Feed Law 
Review 361 
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Exports from the U.S. of agricultural products to EU countries totalled $11.9 billion in 
2013. The EU countries together would rank fifth as an agricultural export market for 
the United States. Leading categories include: tree nuts ($2.3 billion), soybeans ($1.5 
billion), soybean meal ($860 million), wine and beer ($649 million), and prepared food 
($492 million)78. U.S. imports of agricultural products from EU countries totalled $17.6 
billion in 2013. The European Union ranks third behind Canada and Mexico as a 
supplier of Agricultural imports to the United States.  Leading categories include: wine 
and beer ($5.2 billion), essential oils ($2.2 billion), snack foods (including chocolate) 
($1.3 billion), vegetable oils ($955 million), and processed fruits and vegetables ($939 
million). Food makes up £19.5bn or 10% of all current US FDI to the UK alone, which is 
the third most important sector after financial services and information and 
communication79.  
 
Health will be impacted by provisions relating to food within TTIP, with a particular 
focus on the food standards and food inspection regimes. Whilst there is on-going 
debate regarding the merits of systems that have marked differences, it is worthy of 
note to compare current levels of harm related to food in the US and Europe. The 
Centers for Disease Control and Prevention (CDC) estimates that each year roughly 1 
in 6 Americans (or 48 million people) gets sick, 128,000 are hospitalized, and 3,000 die 
of foodborne diseases80. By comparison the European Union had 48,964 cases and 46 
deaths in 2009, the most recent year tallied81. Yet establishing a clear baseline position 
is not straightforward as a further study considers there to be relatively little difference 
between the two trading blocs with regard to food borne illness. A recent comparative 
study by The Acheson Group, LLC (TAG), led by Dr. David Acheson found that on the 
illness rates that the US has lower levels across a group of the most common food 
borne illnesses than in the EU82.  
 
Food standards and regulation represent an important element of FTAs, with significant 
efforts put into supporting broader market access across signatory countries. The 
principle approach to food standards is to ensure that a framework for mutual 
recognition is introduced that will facilitate improved market access. This does not in 
itself provide an ex-ante case of regulatory dilution, but the very practicalities of 
allowing for minimum regulatory requirements could be viewed to be problematic within 
a public health realm. 
 
Both the European and US systems have faced recent challenges. In the US Robert 
Tauxe, the deputy director of the CDC’s Division of Foodborne, Bacterial and Mycotic 
Diseases has stated:  
 
“We recognize that we have reached a plateau in the prevention of foodborne 
disease, and there must be new efforts to develop and evaluate food-safety 
practices from the farm to the table.”83 
 
                                                             
78 http://www.ustr.gov/countries-regions/europe-middle-east/europe/european-union 
79 Poulsen et al Costs and Benefits of an EU-USA Investment Protection Treaty, April 2013 
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81 http://www.scientificamerican.com/article/food-poisonings-hidden-legacy/ 
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What this suggests is that in the US as in Europe there are increasing challenges with 
respect to meeting consumer demand for agri-food whilst ensuring that food safety 
issues are addressed. The SPS chapter of TTIP is predicated upon a commitment to 
ensure food safety, but agreement on the best means to achieve this are yet to be 
reached. 
 
5.3.1 Food Safety 
Food safety and inspection standards in the US and EU are based upon fundamentally 
different regulatory principles with differences manifesting themselves in relation to 
where, when and how products are subject to regulatory assessment. 
 
The varying approach to food standards is illustrated well be the issue of irradiation. 
Whilst foodstuffs are subject to irradiation on both sides of the Atlantic, it has been an 
issue that has raised significant concern within sections of stakeholder opinion. 
Organisations such as the Center for Food Safety argue that TTIP would lead to a 
significant increase in food irradiation, which it argues has significant health disbenefits. 
A recent report states that: 
 
“Food irradiation is an after-the-fact “solution” that does nothing to address the 
unsanitary conditions of factory farms, and actually creates a disincentive for 
producers and handlers to take preventative steps in production and 
handling.”84 
 
Yet one proponent of irradiation of food states that it is another important tool, one that 
is safe and effective but that has been vastly under-used, largely due to opposition 
from the organic food lobby and to government over-regulation.  According to Michael 
Osterholm, director of the Center for Infectious Disease Research and Policy at the 
University of Minnesota  
 
“If even 50% of meat and poultry consumed in the United States were 
irradiated, the potential impact of food borne disease would be a reduction [of] 
900,000 cases and 300 deaths”.85 
 
In the US the Institute for Agriculture and Trade Policy has produced two papers on the 
public health problems in the draft TTIP chapter on Sanitary and Phytosanitary (SPS) 
issues and they question whether the standards, were they to be implemented could be 
enforced. They draw attention to the high cost in the US of foodborne illness (“$33 
billion annually”)86.  
 
The example of whether imports from the United States of chlorine treated chicken 
would be allowable is based upon the assumption that TTIP will agree mutual 
recognition of existing food standards within the United States. Yet behind this issue 
lies a more fundamental concern regarding the principles that underpin any programme 
of regulatory cooperation. For foodstuffs this can be illustrated by the debate as to 
whether to adopt a supply chain ‘farm to table’ approach to food safety or to adopt the 
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US approach, which focuses its food standards approach at a single end point in the 
supply chain.  
 
A paper published in July 2014 by the Institute for Agriculture and Trade Policy (IATP) 
sets out the fundamental concerns with food safety as they relate to TTIP, much of 
which relates to SPS regulations. Simply put the challenge is that current discussions 
suggest that SPS is being subordinated to maximising trade87. Dr Steve Suppan, 
IATP’s author of the paper stated: 
 
 “While many key details regarding things like GMOs are still hidden, its clear 
public health is losing out to corporate interests in a big way”. 
 
 A centre for Food Safety report published in May 2014 provided further detail of the 
potential impact of TTIP on both sides of the Atlantic88. The report sets out a host of 
difficult food products that are currently restricted in the US or the EU, which could 
become legal across the FTA area under the terms of TTIP.  
 
The key part of the discussions will be the extent to which current regulatory provisions 
are deemed to be of ‘equivalent level’. If they are then the risk to health may be posed 
where evidence suggests that the US systems and cross border trade may increase 
health risk. There is evidence of levelling down of cross border food monitoring with a 
case of a Hepatitis A outbreak relating to strawberries imported from Mexico to the 
USA cited by many civil society bodies as demonstrating how NAFTA had led to 
regulatory relaxation89.   
 
TTIP would see the introduction of a Regulatory Cooperation Council to “converge” 
regulatory measures, such as food labelling requirements or environmental standards, 
which would be consistent with proposals offered by the U.S. Chamber of Commerce 
and Business- Europe.  
 
5.3.2 Summary Assessment 
No evidence has been found that the TTIP provisions on SPS could lead to a reduction 
in foodborne disease. Three potentially negative impacts on food safety have been 
identified. The first is that increased cross border trade in agri-food produce on the 
basis of mutual recognition of existing food testing arrangements could increase health 
risks as increased cross border trade leads to intermittent outbreaks of disease. It is 
difficult to estimate the potential impact of this as it would be dependant on the number 
and scale of any outbreaks resulting from cross border trade. It should also be noted 
that such incidents are also a feature of intra EU trade. The second area of risk relates 
to whether TTIP would seek to lift current restrictions on the importing of currently 
banned produce such as hormone treated beef, chlorine washed meat and genetically 
modified (GM) produce. Yet even if this were to happen, it is uncertain as to what the 
potential impact maybe as there is limited evidence on actual, as opposed to potential 
levels of risk. The third level of risk arises from any long regulatory pressures to 
converge food safety systems operating in the US and the EU.  
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Yet at the heart of this discussion is whether techniques such as chlorination provide a 
safe, efficient and effective means to ensure food safety or whether their very use 
signals fundamental food safety problems across the supply chain and that a more 
fundamental assessment of sustainable food safety is required. The introduction of 
TTIP presents an opportunity to level up international food standards and to provide an 
enhanced platform for current pan-European work to improve food safety, yet the 
challenge is that such levelling up could be viewed to constitute a barrier to trade. 
Whether this could be addressed by framing it within a broader benefits assessment of 
TTIP will be based in part on being able to establish such a broader framework for 
assessing cost benefit. 
 
5.4 Trade in Services 
Services constitute an important aspect of TTIP and within this sector government 
procurement will be of particular relevance to health.  
 
‘Public services’ is not a term used in the international trade arena. The World Trade 
Organization defines that only ‘services supplied in the exercise of government 
authority’ and only on a non-commercial basis and not in competition with other 
suppliers, are exempt from trade liberalisation. This narrow definition, with narrow 
protection, is used in trade deals such as TTIP.  
 
Within the EU, the Lisbon Treaty divides ‘services of general interest’, – its term for 
public services – between ‘services of general economic interest’ i.e. essentially 
commercial, and ‘noneconomic services of general interest’. The latter are protected 
but are very few, for example, judicial services. The former, clearly potentially 
commercial, is almost everything including health. 
 
The negotiations for TTIP are on-going but a helpful starting point for an assessment of 
these issues is the CETA between Canada and the European Union. Often cited as 
being in part a test ground for TTIP, it is of note that within the published Services and 
Investment Chapter both health and education services are excluded, and that within 
the Government Procurement Chapter provision is given to maintain preference for 
domestic providers within the health sector.  
 
5.4.1 Public Procurement 
There are a number of issues relating to health that focus more on public 
procurement90. Like a number of the Chapters being negotiated within TTIP the chapter 
on Public Procurement is aligned to global programmes set by the WTO.  There is in 
particular a link to the GPA provisions, with the stated ambition of helping to develop 
“GPA plus” elements. In relation to Public Procurement the initial EU Position Paper 
stated that:  
 
                                                             
90 Services and public procurement dominate 6th TTIP round, Borderlex July 2014. 
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“Discussions on additional elements of coverage, such as state-owned 
enterprises, public undertakings and private companies with exclusive rights 
may require the introduction of additional definitions and related rules”91. 
 
A central tenant of FTAs is to open markets for goods and services to greater 
competition and as such there is a consequent challenge faced by countries that 
currently protect elements of their economy. Richard Craven from Northumbria 
University in his paper in Public Procurement Law Review argues that, in the context of 
public procurement law, successful TTIP talks could potentially be dramatic, both for 
the EU and US, as well as globally92. The EU and US have been at the forefront of 
multilateral and plurilateral efforts aimed at liberalising procurement markets. Of 
particular interest is the contention of Craven’s that it appears to be the case that it is 
the EU as much or more than the US that have proved to be intent on advancing the 
reciprocal opening of procurement markets bilaterally. The expressed intentions are 
ambitious, seeking to agree a public procurement chapter that involves enhanced rules 
and coverage to those of the WTO Agreement on Government Procurement (GPA). 
Craven believes that the EU may see itself as having the most to gain, as infrastructure 
spending remains a focus of US economic recovery93. Cited in Borderlex.eu, the online 
news service that is part of Business New Europe, US Chief Negotiator Daniel 
Mullaney however, has described this as being a ‘myth’94.   
 
The EU industry lobby is supportive of a broad opening up of public procurement. 
Business Europe set their ideas out as follows: 
 
“Given the importance of public purchases by governments of goods, services 
and works, procurement commitments under the Agreement on Government 
Procurement of the WTO (GPA) should be expanded in terms of coverage, at 
all level of government and public entities, lowering the existing thresholds and 
ensuring transparency as well as open and predictable procedural 
requirements.”  
 
Within this context one can consider the particular situation relating to health services.  
5.4.2 Health Services 
Whilst the official line from European Commission negotiators is that health services 
would not be impacted by TTIP there remains a clearly articulated view coming from 
industry and some elements of Member State governments resistant to a blanket 
exemption for health and keen to consider the potential benefits that could accrue to 
health from greater levels of market liberalisation. One of the most recent comments by 
a government Minister in the UK was quoted as saying that they “should be included 
because Britain’s healthcare industry is a major exporter and would benefit from more 
                                                             
91 EU - US TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP Public 
Procurement Initial EU position paper 2013 
92  
EU-US Transatlantic Trade and Investment Partnership Agreement: The European Commission's Negotiating Position on Public 
Procurement / Craven, Richard. 
In: Public Procurement Law Review, 2014, issue 3, pp. NA65-NA76 (RA 634) 
93 Public Procurement and the EU-US Transatlantic Trade and Investment Partnership Agreement: The EU Negotiating Position 
Richard Craven, University of Northumbria at Newcastle 
 
94 Services and public procurement dominate 6th TTIP round, Borderlex July 2014. 
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open trade” although he does not state whether he is referring to trade in health goods 
or health services or both95.  
 
There are both general and specific concerns that have been expressed in relation to 
the potential opening up of health services to increased market competition. Firstly, in 
relation to conditions of employment, there is a broadly articulated contention that if the 
private sector including US providers were to have wider access to health service 
delivery, then terms and conditions of employment could be affected.  
 
Healthcare is a highly labour intensive activity and one of the largest sectors in the EU. 
A recent European Commission study reported that in 2010 there were around 17m 
jobs in the healthcare sector, which represented 8% of all jobs in the then EU-2796. 
Taking just one example in the United Kingdom, it is apparent that the healthcare 
workforce is increasing both in overall terms and as a percentage of the public sector 
workforce97. In the UK, the public sector health and education workforce now accounts 
for more than half of state employees, a significant increase over the last decades.  
 
TTIP presents a challenge to this situation if it facilitates greater involvement by private 
sector healthcare providers, but the potential impact of this on employment, wage and 
productivity levels is less certain. In other historically traditional areas of public sector 
employment that have been subject to market-based reform, there is evidence of short, 
medium and long term changes to employment levels and conditions, although with 
limited clear trends9899. A further example is the PIQUE project, which was a broader 
ranging comparative European study on the impact of privatisation on employment100. 
The study found that liberalisation and privatisation of public services have largely 
negative effects on employment and working conditions and varied effects on 
productivity and service quality. In addition it found that those positive effects and 
better performance as compared to other countries were mostly the result of superior 
regulation, rather than of competition or private corporate initiative. 
 
In addition to the challenges posed to the health workforce by any extension to 
privatisation that might result from the implementation of the TTIP, additional concern 
has been voiced in relation to the suitability of private contracting arrangements to 
health services. The largest range of studies relate to the UK National Health Service 
with those such as a study undertaken by the Public Services International Research 
Unit at Greenwich University that found that “Outsourcing of clinical services through 
ISTCs and GPs ‘out of hours’ services shows some negative effects on patient care, 
poor value for money as well as evidence of inadequate monitoring and evaluation of 
the services101. Tim Albrecht’s paper in the European Journal of Public Health on 
European privatisation of health services concluded that “Universal privatization in 
                                                             
95 http://www.independent.co.uk/news/business/news/ttip-trade-agreement-critics-driven-by-antiamerican-sentiment-says-
minister-lord-livingston-9705331.html 
96 2012 European Commission Staff Working Document on an Action Plan for the EU Health Workforce 
97 J. Cribb et al (2014) The public sector workforce: past, present and future IFS Briefing Note BN145 
98 R, Pedersini (1999) European industrial relations observatory on-line 
99 Hermann, Jo ̈rg Flecker (2009) Privatisation of Public Services and the Impact on Quality, Employment and Productivity 
(PIQUE) – Final Report 
100 http://cordis.europa.eu/documents/documentlibrary/122489371EN6.pdf 
101 http://www.psiru.org/reports/broken-promises-impact-outsourcing-nhs-services 
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health care challenges the most important principles of socialized health care, while 
providing insufficient proven ‘benefits’”102. 
 
This in of itself does not provide substantive empirical evidence regarding the 
privatisation of European health services, nor does it mean that TTIP would necessarily 
increase the possibility of seeing the widespread privatisation of health services. 
However, it does as a minimum provide context as to why the issue of sector exclusion 
for health has been a significant theme within the current discussions. 
 
5.4.3 Sector Exclusions 
The first major FTA involving the US was NAFTA. Within this the Canadian 
Government negotiated a ‘cave out’ for health. What this meant in practice was that 
Chapter 10 Annex 1001.1b-2: Services Section B of NAFTA excluded Health to the 
extent that healthcare is a ‘social service’ and it is maintained or provided for a ‘social 
purpose’. To date it does not appear that NAFTA has resulted in any reduction of the 
regulatory health policy space, but the wording of the exclusion is considered by 
commentators to be important as it aligns the exclusion to health remaining a ‘social’ 
rather than a ‘commercial’ service.  
 
There are different levels of exclusion and it does not appear to be the case that the 
EU is currently seeking to exempt health in the manner that Canada has from NAFTA. 
EU negotiators have made a clear commitment that there will be an exemption for 
public services from TTIP and that this exclusion will include publicly run health 
services. However, this is a complex area and evidence suggests that the difference 
between a ‘hard exclusion’ or ‘carve out’ and a soft exclusion’ or ‘voluntary exemption’ 
will be central to establishing whether and how health services may be impacted by 
TTIP. 
 
What may be termed a ‘hard exclusion’ or ‘carve out’ of health within TTIP would 
exclude health services from market access provisions, but would not ring-fence goods 
such as pharmaceuticals and medical devices. If, however, there is only an ‘soft 
exclusion’ as is the case with the proposed CETA, then individual Member States 
would have to make an explicit decision whether to include or exclude their national 
health services. This links to whether there will be a positive ‘op in’ or negative ‘opt out’ 
approach within the services chapter of TTIP, although no Member State has to date 
formally set out its position.  
 
5.4.4 Summary Assessment 
The extent to which the market now plays a direct role in health services is evident 
across the EU, although it would be reasonable to still describe health as being a public 
service. But what makes a public service public? Funding, regulation, management and 
delivery all play a part. There is no sense that the funding arrangements for health 
services would be under any form of threat, nor in theory would the government’s role 
in health policy and regulation. Yet it is evident that the protection offered to health 
services in early FTAs such as NAFTA are broader than those being proposed for 
CETA and TTIP. In addition the environment in Europe is a different one to that in 
Canada at the time NAFTA was being negotiated in that the boundaries of ‘social’ as 
                                                             
102 http://eurpub.oxfordjournals.org/content/19/5/448 
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opposed to ‘commercial’ continue to blur, which will make the precise wording of any 
‘hard’ or ‘soft’ exclusion all the more important. 
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5.5 Investor Protection 
Originally, any grievances a foreign investor had with the host state could only be 
pursued through the domestic courts of that state or through diplomatic espousal103. 
However, with the advent of bilateral investment treaties (BITs) came Investor-State 
Dispute Settlement (ISDS), deemed by proponents to be a more secure and direct 
means of investment protection. The first BIT was between West Germany and 
Pakistan in 1959. This led to the establishment of the International Centre for 
Settlement of Investment Disputes (ICSID) and United Nations Commission on 
International Trade Law (UNCITRAL) in 1966. UNCITRAL provides rules of arbitration 
for ISDS as well as a forum, venue, secretariat and expertise. 
 
5.5.1 ISDS 
Under ISDS, foreign investors may bring a damages claim against the host state in an 
independent tribunal. Typically these treaty commitments include compensation for 
expropriation, non-discrimination between foreign and domestic investors, free transfer 
of capital and a guarantee of minimum standards of treatment.  
 
There is no requirement for the investor to exhaust domestic legal proceedings in either 
country before bringing an ISDS case before an international tribunal. The tribunal is 
made up of three arbiters, one chosen by the claimant, one by the defender and one 
chosen mutually. Proceedings are confidential. 
 
A 2014 article written by Corporate Europe highlights that a key question for winning 
damages involves an assessment as to whether government policies can be construed 
as “equivalent to expropriation”. The point made is that this argument is made even 
though the investor’s physical assets are not physically taken104. The definition of 
indirect expropriation provides the basis for action against governments on the basis 
that this could potentially impact on future profits.  
 
As argued in an article in The Nation by William Greider, a critic of FTAs, enshrining 
this doctrine of ‘indirect expropriation’ into trade pacts was part of “a long term strategy, 
carefully thought out by business” to re-define “public regulation as a government 
‘taking’ of private property that requires compensation”105. The implications, according 
to Greider, are far-reaching: 
 
"Because any new regulation is bound to have some economic impact on 
private assets, this doctrine is a formula to shrink the reach of modern 
government and cripple the regulatory state – undermining long-established 
protections for social welfare and economic justice, environmental values and 
                                                             
103 In this setting, diplomatic espousal refers to the ability of a state to seek damages from the host state on behalf of an 
aggrieved national at the state-state legal level. 
104 http://corporateeurope.org/printpdf/1802 
105 http://www.thenation.com/article/right-and-us-trade-law-invalidating-20th-century# 
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individual rights. Right-wing advocates frankly state that objective – restoring 
the primacy of property against society’s broader claims.”106 
 
The selection of arbiters (one by both parties, the third by consensus) appears at first 
glance to create a neutral panel overall. However, concerns are raised regarding public 
health cases by the need to obtain a majority decision. There are relatively few arbiters 
with a public health background.  
 
Furthermore critics argue that arbitrators’ dependence on private appointments may 
bias them towards the private sector, as allowing through one particular case may open 
the gates for far more. It was found that 55% of ISDS cases today involved the same 
15 lawyers.107 
 
5.5.2 History of ISDS 
ISDS was used relatively infrequently until the 1990s, but by 2002 30 cases were being 
filed a year, and by 2012 more than 60 cases were being filed108. The turning point 
came after it was clear that the Uruguay round of GATT did not provide sufficient 
regulatory environment for investors. ISDS measures were being forwarded in a 
number of ways. Firstly, ISDS has been embedded in BITs, which began to proliferate 
in the early 1990s. Such BITs included the Hong Kong-Australia treaty, which 
subsequently allowed Philip Morris to fight the plain tobacco packaging law in Australia. 
To date, there are nearly 3,000 BITs in operation.109 In NAFTA, the first regional FTA to 
introduce ISDS, which was signed in 1994 the ISDS provision was designed to protect 
investments against Mexican government seizures of US and Canadian businesses, a 
risk that has basis in the history of Latin America (evidenced, for example, by the 
nationalisation of Mexican oil industry in 1938). Finally negotiations on a Multilateral 
Agreement on Investment (MAI) started in 1995, which attempted to supersede the 
‘spaghetti bowl’ of BITs by standardising international investment law and setting ISDS 
as a standard measure.110 
 
All trade agreements have forms of legal remedy. The most developed is ISDS, but 
others exist. The EU-Korean FTA has followed the WTO Dispute Settlement 
Understanding, with provision for ‘proportionate sanctions’. There are other non-binding 
mediation mechanisms. The US-Korean FTA does have ISDS. The US-Australian FTA 
does not have ISDS but TPP covering the same states will include it. 
 
5.5.3 Impact of ISDS 
An in-depth study prepared for the Netherlands Ministry for Foreign Affairs broadly 
welcomes the inclusion of ISDS in the TTIP agreement and claims that of the 260+ 
ISDS cases worldwide  - “Legislative acts are subject to ISDS procedures only in 
                                                             
106 Op Cit 
107 http://www.citizen.org/documents/NAFTA-at-20.pdf 
108 http://www.jura.fu-berlin.de/fachbereich/einrichtungen/oeffentliches-recht/lehrende/hindelangs/Studie-fuer-
Europaeisches-Parlament/Volume-2-Studies.pdf?1411545557 
109 http://unctad.org/en/PublicationsLibrary/webdiaepcb2013d9_en.pdf 
110 The MAI negotiations were between OECD countries, and its implementation was to have been open to developing 
countries. Its draft went public in 1997 and, amongst other provisions, proposed restrictions in governments’ ability to limit 
market access of foreign multinationals. These measures were to be backed up with NAFTA-style ISDS tribunals. 
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exceptional cases, and these claims are hardly, if ever, successful”111.  A commonly 
cited example of ISDS being used to challenge government in the field of health policy 
was the Dutch firm Achmea who initiated arbitration proceedings against Slovakia over 
the impending expropriation of private health insurance companies, which linked to the 
Slovak government’s plans to launch a single state-operated health insurance 
company. The Dutch company argued that expropriation would not be in the public 
interest, subject to due process of law, and would be discriminatory. This case was 
resolved in favour of the Slovakian Government with the Arbitration Court ruling that it 
had “…no right to interfere with the democratic process of a sovereign state and has no 
jurisdiction to adjudicate in this matter”112. 
 
Barker, writing for the Atlantic Community, a think tank that receives both US and 
German state funding, broadly concurs stating that given the relatively short track 
record by which to judge FTAs, it is difficult to ascertain how ISDS may develop over 
the next decades. In a briefing for the European Policy Centre Pardo argues that the 
exclusion of ISDS could have a negative effect on European business, with reduced 
levels of inward investment113. 
 
Yet many other stakeholders continue to see significant risk to public services and 
public policy in ISDS as a dispute resolution mechanism. To highlight just one example 
Ikenson, in a report for the libertarian Cato Institute, lists “Eight good reasons to drop 
ISDS from TPP and TTIP”114. Concern is also now being voiced by a number of 
national governments. Australia has recently renewed its FTA with Japan, which was 
first arranged 12 years after the end of the Second World War and which still does not 
include an ISDS115. One of their Senators, under pressure from groups anticipating 
higher medicine prices, is attempting to introduce a bill banning ISDS clauses from 
international trade and investment agreements116.  The Austrian Federal Chamber of 
Labour held a panel discussion last March when misgivings re ISDS were expressed. 
Indonesia is currently cancelling all its FTAs that have ISDS. Of greatest potential 
impact are current views emanating from the German Government suggesting that they 
now have serious concerns regarding the inclusion of ISDS in TTIP117. 
  
5.5.4 Health and ISDS 
Two central risks to health have been identified. The first is that ISDS could impact 
within the arena of public procurement and in particular on the ability of governments to 
bring previously privatised health services back into the state sector. The use of a 
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‘ratchet clause’ has been cited as a means by which companies currently providing 
outsourced health services could claim for ‘indirect appropriation’ of future profits were 
such services to be terminated or returned to the state sector. This concern over 
renationalisation has arisen from the cases in Poland and Slovakia where such as 
situation occurred, both of which are often cited by critical stakeholder groups118. Given 
that the UK Labour Party for one is currently considering options for the future of the 
National Health Service and in particular to reverse elements of the country’s Health 
and Social Care Act the potential impact of TTIP will remain a key area of focus. 
 
A second potential risk of ISDS to health relates to ability of governments to regulate in 
the public interest. (This issue is further discussed in the Chapter on Health Policy 
Space.) 
 
5.5.5 TTIP and ISDS 
The inclusion of ISDS is currently the subject of a formal Public Consultation exercise 
that has been instigated by the European Commission and Member States such as 
Germany now publically airing doubts about its relevance of such a mechanism for two 
MDCs with developed national legal systems. Given that the European Commission 
has yet to publish the results of the formal Public Consultation, it is likely that further 
pressure will be applied to either removing or fundamentally reassessing the provisions 
within ISDS.  
 
5.5.6 Summary Assessment 
An assessment of evidence and opinion pieces suggests the proposed inclusion of 
ISDS into TTIP as being the single most contentious issue within the current 
negotiating process. Yet ISDS is already present in a number of existing bilateral 
agreements, it is used proportionately more by European based companies than those 
in the US, it does have a limited positive impact on levels of external investment and 
only a minority of cases are brought by business against government and awarded 
financial penalties have in most cases been significantly lower than those requested. 
Yet ratchet clauses have been invoked and there have been notable if limited 
examples of public health policy being challenged by means of ISDS. It is also 
apparent that a limited number of Member States are now raising public doubts about 
its inclusion within TTIP. Whatever the final decision with regard to TTIP this evidence 
assessment has established that perceived risks to the health policy space have not 
been fully substantiated. In addition consideration should be given as to whether an 
ISDS clause in TTIP that has been modified to provide additional safeguards against 
unwarranted claims by business against government would provide greater or lesser 
protection than the existing patchwork of BITs.  
  
                                                             
118 http://www.tuc.org.uk/international-issues/tuc-submission-european-commissions-consultation-isds 
 49 
 
 
5.6 Intellectual property  
Intellectual property relates to many areas of the proposed TTIP of which 
pharmaceuticals is from a health perspective of particular importance. The cost to 
Europe of pharmaceuticals was estimated by the OECD to have been €190bn in 2010, 
which equates to an average of 1.5% of GDP across European Member States119. The 
European pharmaceutical industry is also a significant source of investment and 
employment. The European trade association EFPIA estimates that n 2012 
pharmaceutical companies invested an estimated € 30 million in research and 
development in Europe and that it directly employs 700,000 people and generates 
three to four times more employment indirectly120. 
 
In relation to IP one pharmaceutical industry position statement has articulated a level 
of ambition for the TTIP believing it to be: 
 
“A once-in-a-generation opportunity for the EU and US to set aligned high-
standards for intellectual property (IP) protection and enforcement. This will 
contribute to incentivising the development of innovative medicines that meet 
patients' needs.”121 
 
Potential intellectual property revision has also been highlighted by a range of 
stakeholder groups as constituting one of the major risks to European health systems. 
Reports such as the Commons Network/ Medicines in Europe Forums Position Paper, 
which presents IP reform to be one of five major risks presented by the TTIP 
negotiations122. 
 
There are important differences between EU and US patentability standards that could 
impact on how pharmaceuticals are regulated in the EU such differences relate to what 
prior user rights are based on and how they are defined. There are also differences in 
how patent applications are handled and patentability determined123.  
 
The first issue to address is Regulatory Data Protection (RDP) and patent protection. It 
is argued that the need for RDP protection has arisen because the testing required to 
secure regulatory approvals has become more extensive and expensive124. Under 
European pharmaceutical law innovator pharmaceutical companies are granted a 
period of regulatory data exclusivity in which a generic applicant cannot refer to the 
innovator's data to obtain a marketing authorisation. The European legislation was 
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amended in 2004 and currently contains a period of eight plus two (plus one) years of 
regulatory data protection (RDP)125. 
 
Critics believe the extension of RDP on biological medicinal products in the EU to be 
problematic. In the US protection currently stands at four years with an added eight 
years for Market Exclusivity. It is argued by some stakeholder groups that the inclusion 
of terms of 12 years for biologics – as the US has proposed in the TPP - would lock in 
this term for both the US and the EU, with the concomitant potential to delay the 
introduction of cheaper generic biosimilars into the European market126.  
 
According to an Oxfam study pharmaceutical companies have gradually shifted their 
business model from focusing on therapeutic innovation towards marketing schemes, 
and expanding patent protection127. A joint position statement from organisations 
highlights patent linkage as one of the means by which TTIP may seek such patent 
extensions128. Patent linkage refers to the linking of marketing authorisation for a 
medicine to its patent status. Linkage to patent status is argued to cause delays in 
generics reaching the market and if TTIP included provisions relating to patent linkage 
then regulatory authorities would only be able to start the licensing process when the 
patent is terminated, a situation that is not currently legal in the EU. Critics cite patent 
linkage as a means to slow the introduction of potentially lower priced generic 
alternatives129.  
 
A recent briefing from the NHS Confederation, an employers stakeholder group 
suggests that there are additional IP risks within the proposed TTIP. 
 
“The more stringent intellectual property rights in force in the USA could, if 
extended to the EU, affect the health sector negatively. Extending patent 
protection to interventions such as diagnostic, therapeutic and surgical 
procedures could limit and/ or delay patient access to innovative treatments and 
medicines and to cheaper generic drugs.130” 
 
It should be recognised that there is already a high level of alignment between the US 
and EU such that for instance that Bolar principles131 apply in broadly similar manner 
on both sides of the Atlantic, meaning that generics can conclude regulatory 
requirements prior to the expiry of the originator patent (but not commercialise before 
then). However it is of note that the European Generics Association in their position 
paper on TTIP contest that “…we strongly recommend not to attempt creating 
harmonisation in this area, but to recognise the different approaches between the 
parties”132. 
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From a research based pharmaceutical industry perspective voices such as Eli Lilly are 
calling for TTIP to address IP related issues such as to provide for the early resolution 
of patent disputes before an infringing product is launched on the market, arguing that 
a lack of predictability over enforcement in Europe is damaging for innovative 
companies and should be addressed in TTIP.  
 
No estimates of the potential cost impact of pharmaceutical related IP changes in TTIP 
have been identified during this review. However, critics of CETA such as the Canadian 
Health Coalition have quoted research study assessments of a potential increase in 
costs for the Canadian drugs budget that will result from similar IP changes in CETA to 
be in the region of 15%133. Nonetheless, there are a number of factors that may limit 
the ability to use such estimates to inform the likely impact of TTIP on pharmaceutical 
prices in Europe, most important of which are the significantly higher generics costs in 
Canada by comparison with Europe134.   
 
5.6.1 Summary Assessment 
The interplay between research based and generics pharmaceutical companies based 
in Europe and those based abroad, makes an overall assessment of IP in relation to 
pharmaceuticals challenging. Yet the manner in which market and regulatory drivers 
relating to IP are addressed within TTIP could have a material impact on access to and 
affordability of medicines in Europe, as well as well as being a determining factor in 
shaping the future of the European pharmaceutical industry. The enhancement of IP 
provisions is an area of common agreement between the US and European 
negotiators, which is likely to provide the pharmaceutical industry with a lever to 
achieve their goal of strengthening the commitment to IP, which they argue to be 
necessary for the long term sustainability of the European research based industry. 
The broader policy debate will focus on the balance between these market needs with 
regulatory needs. Within this context, the drivers for potential increases in drug prices 
as a result of TTIP implementation should be carefully assessed as should the potential 
impact on access to medicines, especially when is it not possible to set these against a 
value that may or may not accrue from regulatory improvements. 
  
                                                             
133 http://openparliament.ca/committees/international-trade/41-2/13/michael-mcbane-1/only/ 
134 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3999558/ 
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6.0 Regulatory Cooperation and Reform 
One of the fundamental differentiators between the TTIP and other FTAs is the explicit 
commitment to establish it as a ‘living agreement’. This commitment to on-going 
regulatory reform presents opportunities to improve health related regulation, but it also 
presents a risk of regulatory dilution. 
 
A primary stated objective of FTAs is reducing regulatory burdens for business, as a 
central element of providing an enhanced platform for free trade. Yet negotiators have 
regularly restated the principles underpinning regulatory reform to provide assurances 
that TTIP will not have a negative impact on population health. The position of EU trade 
commissioner Karel De Gucht is that EU standards were sacrosanct. He said in the 
summer of 2014: 
 
“Let me be clear on this very important point: we are not lowering standards in TTIP. 
Our standards on consumer protection, on the environment, on data protection and on 
food are not up for negotiation. There is no “give and take” on standards in TTIP.”135 
 
The arguments on both sides are not straightforward in that the key to understanding 
regulatory cooperation lies in the manner in which a small number of words or phrases 
are interpreted by policy makers and regulators, and how these relate to the to the 
arena of health policy and practice.  
6.1 Comparative approaches to Regulation 
As has previously been discussed there are fundamental differences in the manner in 
which the US approaches the issue of regulation when compared to the situation in 
Europe. The most important single distinguisher is that while the US adopts an 
evidence-based risk assessment approach, Europe adopts a precautionary approach 
where the starting point is an assessment of potential risk, even where a full evidence 
base may not be available. Whilst this may at first appear to be a simple matter of 
looking down the same barrel from different ends, the reality is that it can and does 
lead to significantly different regulatory outcomes. This issue is discussed further in the 
section on the precautionary principle. 
 
Firstly, there is the idea of compatibility. The WTO asserts that technical barriers to 
international trade could be eliminated if Members accept that technical regulations 
different from their own fulfil the same policy objectives, even if through different 
means. This approach is based on the European Community's 1985 “new approach” to 
standardization. Secondly, there is the concept of equivalence in regulatory practice, 
which presupposes that FTAs such as TTIP do not require participating countries to 
adopt the same regulatory practices with regulatory convergence focussed on 
increased mutual recognition of existing practices. However, it would be reasonable to 
assert that the underlying principle of FTAs is to see regulatory practice simplified. 
Whilst one can make a connection between simple and less, it would not be 
reasonable to assume less must automatically mean weaker or poorer regulation. 
Finally one may consider full-scale harmonisation in the sense of agreeing on the exact 
same rules is not under consideration for TTIP and it is known from documents 
                                                             
135 http://www.theguardian.com/environment/2014/mar/14/free-trade-deal-eu-us-environment-ngos-sustainability 
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released under FOI requests that the European Commission has considered different 
options such as ‘compatibility’, ‘mutual recognition’ and ‘equivalence’. Judging from the 
released documents, ‘equivalence’ seems to have been the commission’s preferred 
option, meaning that the EU and US would consider their regulations to be of 
equivalent and thus acceptable standard. This would mean that US firms could follow 
US regulations when exporting to and investing in Europe.136 
 
Once again, there are differences in the US and European approaches to structuring 
regulatory processes. This is most clearly characterised in the area of food regulation, 
where the US approach traditionally favours a single point of regulation which could 
result in a reduction in costs. By contrast, the European approach favours multiple 
regulatory checks as encapsulated in the concept of ‘farm to table’ food regulation. 
 
6.1.1 Precautionary and Risk Approaches 
Central to the idea of regulatory coherence is the establishment of guiding principles 
that underpin the process of review and change. As has been stated earlier the EU and 
US come from distinct starting positions, each of which has a historical as well as 
constitutional basis. These need to be understood alongside the political assessment 
as to whether FTAs are more free market or social market in orientation.  
 
The social market approach is generally associated with the precautionary principle. 
The precautionary principle itself has international roots but is very much seen to be a 
fundamental plank of the European Union and its approach to regulation. The specific 
term "precautionary principle" originated from Principle 15 of the Rio Declaration on 
Development and the Environment (part of the United Nations Environment 
Programme)137. Principle 15 would permit a "precautionary approach" when there are 
threats of "serious or irreversible damage" to the environment. Of particular relevance 
is that Principle 15 states that a "lack of full scientific certainty shall not be used as a 
reason for postponing cost-effective measures to prevent environmental degradation." 
Equally Article 191 of the Lisbon Treaty states that in relation to EU position on 
environmental protection “…shall be based on the precautionary principle and on the 
principles that preventive action should be taken, that environmental damage should as 
a priority be rectified at source and that the polluter should pay”138. 
 
The free market approach focuses on an approach built around evidence based risk 
assessment. Nor can it be assumed that one model is underpinned by a higher level of 
commitment to protecting human health and well-being than the other, but rather that 
each is underpinned by a particular approach or methodology. Whilst wishing to avoid 
over simplification it is apparent that the two approaches generate strong stakeholder 
responses. This can be highlighted by the CFA report of a 2013 meeting of business 
representatives in Copenhagen where Shaun Donnelly, a former U.S. trade official now 
lobbying for the U.S. Council for International Business was heard to remark that “TTIP 
is only worth doing if the regulatory side is covered, such as getting rid of the 
precautionary principle.”139  
                                                             
136 http://www.theguardian.com/environment/2014/mar/14/free-trade-deal-eu-us-environment-ngos-sustainability 
137 http://www.unep.org/Documents.Multilingual/Default.asp?DocumentID=78&ArticleID=1163 
138 http://www.lisbon-treaty.org/wcm/the-lisbon-treaty/treaty-on-the-functioning-of-the-european-union-and-
comments/part-3-union-policies-and-internal-actions/title-xx-environment-climate-change/479-article-191.html 
139 http://www.centerforfoodsafety.org/files/cfs_trade_matters_76070.pdf 
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To provide an example of how a risk assessment approach works one may consider 
the sanitary and phytosanitary chapter within an FTA. This chapter would require a 
country wishing to bar imports of a hazardous product, to first show by risk assessment 
that a certain level of harm will occur and cannot be mitigated. For instance, the US 
took the European Union to the World Trade Organisation court, and won a ruling that 
the EU had not proved that harm would occur from importing and eating artificial 
hormone-treated beef from the US140. 
 
It has been noted that the precautionary principle is often worded differently in different 
contexts. Yet at the core of each statement is the idea that action should be taken to 
prevent harm to the environment and human health, even if scientific evidence is 
inconclusive or incomplete. The European Commission Communication on the 
Precautionary Principle in 2000 stated that: 
 
"The precautionary principle applies where scientific evidence is insufficient, 
inconclusive or uncertain and preliminary scientific evaluation indicates that that 
there are reasonable grounds for concern that the potentially dangerous effects 
on the environment, human, animal or plant health may be inconsistent with the 
high level of protection chosen by the EU."  
 
As the principle has been elaborated recently by Nancy Myers implies three additional 
ideas, beyond "harm" and "scientific uncertainty". In an article for the Environmental 
Health Network Myers has identified three aspects of the precautionary principle141:  
 
§ The notion of seeking alternatives to harmful technologies;  
§ The idea of shifting to proponents of a technology the responsibility for 
demonstrating its safety; and  
§ The goal of transparency and democracy in making decisions about 
technologies.  
 
As is highlighted in the thematic assessment of TTIP, regulatory coherence appears to 
be an issue where stakeholders from the United States are putting pressure on 
negotiators to give ground, with the interpretation of mutual recognition being used to 
protect and promote the risk assessment approach alongside the principle of needing 
to be only a single assessment point. On this basis the question is whether there is the 
willingness, scope and capacity to use the opportunity of TTIP to help improve overall 
regulatory efficiency and effectiveness is considered further.  
 
Evidence suggests that, in relation to food safety standards, TTIP could see pressures 
to recognise existing regulatory provisions within each trading bloc. There is evident 
opposition to approaches such as ‘farm to table’ that align to the broader precautionary 
principle underpinning significant elements of European regulation. However in relation 
to food the precautionary principle appears to cut both ways. One commentator 
suggests that: 
 
                                                             
140 O'Brien, M (2001) Beyond Democratization Of Risk Assessment: An Alternative To Risk Assessment (Presented to the Society 
for Risk Analysis, New England Chapter. Boston, MA, December 12, 2001.) 
141 Myers, N (2000) Debating the Precautionary Principle Science and Environmental Health Network 
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“The US government politicians have criticized the precautionary principle, but 
many US laws related to occupational and environmental safety embody 
policies that reflect a precautionary approach, and the US is party to treaties 
that explicitly call for the precautionary principle.”142  
 
This could provide something of a basis to ensure that TTIP works to level up 
standards. Yet the emerging agenda around unhealthy foods could fall foul not just of 
provisions within TTIP but also within existing international trade law provided for by 
the WTO.  
6.2 Summary Assessment 
No current evidence was identified relating to the potential long-term impact of a FTA 
predicated upon a commitment to ongoing reform. As such it is difficult to make an 
assessment as to whether the regulatory reform agenda represents a threat or an 
opportunity to public health. What can be said is that the initial commitment to mutual 
recognition is likely to be reviewed in the medium to long term and that pressures 
towards regulatory convergence could well increase. This then raises the issue as to 
whether convergence will lead to an overall levelling up or down of current standards.  
  
                                                             
142 http://www.consumersinternational.org/media/1402104/tacd-food-resolution-on-the-approach-to-food-and-nutrition-
related-issues-in-the-ttip.pdf 
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7.0 Heath Policy Space 
Health policy space is currently being expanded from an existing policy focus on 
prevention and harm reduction and regulatory domains such as tobacco control, to 
include alcohol, unhealthy foods and related lifestyle issues. Coinciding as this does 
with global trade that is consistently seeking new growth markets, there is evident risk 
of direct and indirect challenge to the right to regulate. FTAs such as TTIP are likely to 
form an important element of the legal basis for mediating this increasingly contested 
space and helping to determine the boundaries of future health policy scope and 
ambition.   
 
The term ‘health policy space’ refers to the ability of nation states and supra-national 
governance bodies such as the European Commission to develop policies and 
practices that improve the health and wellbeing of their citizens. Koivusalo et al define it 
as: 
“…the freedom, scope, and mechanisms that governments have to choose, 
design, and implement public policies to fulfil their aims.”143  
 
The concept was discussed at the 2004 United Nations Conference on Trade and 
Development (UNCTAD), where the consensus document contended that the 
increasing interdependence of national economies in a globalizing world and the 
emergence of rule-based regimes for international economic relations have meant that 
the space for national economic policy, i.e. the scope for domestic policies, especially 
in the areas of trade, investment and industrial development, is now often framed by 
international disciplines, commitments and global market considerations. Koivusalo et 
al contend that: 
 
“Although the only truly global trade treaty body, the WTO is only one part of a 
larger international trade regime. Bilateral and regional agreements, often 
between industrialized and developing countries, are increasing in number and 
importance, particularly as they generally go beyond requirements within WTO 
agreements.”144  
 
The concept of health policy space has been widely discussed. An article by Thow and 
McGrady highlighted a number of the issues relating to the issue of policy space145. 
They assert that: 
 
“Risk management should take place within the framework of existing IIAs, and 
governments must avoid entering into future investment agreements that overly 
constrain their regulatory autonomy with respect to public health nutrition.”  
 
                                                             
143 
http://www.globalhealthequity.ca/electronic%20library/Globalization%20and%20Policy%20Space%20for%20Health%20and
%20Social%20Determinants%20of%20Health.pdf 
144 op cit p108-109 
145 Thow, A.M & McGrady B. Protecting policy space for public health nutrition in an era of international investment agreements 
Bulletin of the World Health Organization 2014;92:139-145 
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Koivusalo et al highlight the potential for FTAs or other related agreements to include 
inadvertent clauses that could later impact on the ability of governments to respond to 
public health needs146.  
 
There are two main challenges to health policy space presented by FTAs such as the 
TTIP. The first of these is direct in terms of potentially prescribing areas of health 
regulation, and the second is more indirect impacting on the propensity of governments 
to instigate new public health initiatives. 
7.1 Regulatory Scope 
There is increasing evidence of government seeking to include regulation within the 
scope of its broader public health policies. This is being observed in the US with the 
recent attempt to limit sales of carbonated sugar drinks, and in Europe with the 
introduction in Scotland of minimum alcohol pricing.  
 
The most relevant example relating to public health and alcohol is that of the Scottish 
government seeking to introduce a minimum price of 50p (€0.63) per unit. The proposal 
has been forwarded on public health grounds, with evidence provided that 
demonstrates both a public health need and the potential for the regulatory instrument 
to positively impact on the problem. The proposed law has faced resistance not just 
from industry, but also from other European countries and the European Commission, 
with legal processes currently on-going147.  
 
By comparison the UK government has recently introduced an ‘alcohol floor price’ 
which provides a complex mechanism which would impact on an estimated one per 
cent of sales in the UK148. The new law has faced challenge from stakeholder groups, 
which say that it will only lead to a maximum drop in consumption of 0.04%, but it is of 
interest that the UK Government has made clear that it wished to make a proposal that 
would address the current legal challenge to the Scottish law149. There is no current 
evidence of the UK law being subject to legal challenge. 
 
Whilst the current Scottish example has no immediate link to the current TTIP 
discussions, it is apparent that if the proposed regulation is already subject to challenge 
on the basis of European internal market law, it could also be subject to challenge from 
international trade law and provisions within TTIP. As such what the minimum alcohol 
pricing example raises is a situation where public health priorities are expanding at the 
same time that trade law is also expanding creating in its wake further scope for 
challenge and conflict.  
 
It appears that where public health regulation seeks to extend the bounds beyond the 
status quo, it becomes at risk of being caught in a complex and multifarious legal web. 
The issues that need once again to be considered is where the boundaries between 
trade law and health law should be drawn, what the respective responsibilities of 
stakeholders should be to ensure that legitimate rights are protected and that agreed 
means of conflict resolution are provided for. 
                                                             
146 Loivusalo p 110 
147 https://www.scotcourts.gov.uk/opinions/2014CSIH38.html 
148 http://www.bbc.co.uk/news/uk-26040550 
149 http://www.blogs.findlaw.co.uk/solicitor/2014/02/uk-government-sets-floor-price-for-alcohol.html 
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7.2 Regulatory Ambition 
There is evidence that the presence of international trade law can and does have an 
impact on public authorities seeking to regulate within ‘health policy space’ but the 
issue under consideration is to differentiate between legitimate input into the policy 
process and illegitimate input. 
7.2.1 Regulatory Chill 
Regulatory chill has been used as a term for the last decade, most particularly within 
the area of environmental policy. At its widest it is used to account for any impact that 
market forces may have on public policy regulators that leads them to refrain from 
developing, introducing or revising regulatory or other legal measures aimed at 
enhancing health protection. This may include the actual or perceived threat of ‘capital 
flight’, but more recently the focus has been on the potential impact of international 
trade law and specifically FTAs150. 
 
Philip Morris International (PMI) used TRIPS as part of its legal arsenal against 
Uruguay’s stricter tobacco packaging rules.151 Claims circulated that Philip Morris was 
seeking billions of dollars’ worth of compensation, until the company revealed in 2010 
that it would seek only $25m. Although PMI cannot use TRIPS to claim compensation, 
it forms the background of the case, providing “legitimate expectations” of the 
regulatory environment.152  
 
The current dispute began in the Australian High Court, where British American 
Tobacco, PMI and the other tobacco companies lost their case of intellectual property 
infringement. This then led the tobacco industry to look to international trade law with 
ISDS provisions with the Hong Kong-Australia FTA used to launch an action in 2012. In 
parallel the tobacco industry has supported countries including Ukraine, Honduras, 
Indonesia, the Dominican Republic and Cuba to raise the issue with the World Trade 
Organisation.   
 
Review is ongoing but recent assessment suggests that the application under the ISDS 
provisions within the Hong Kong-Australia FTA may be dismissed on a technicality153. 
Yet the issue is far from resolution as the issue of ‘treaty shopping’ comes to the fore. 
So too evidence is being presented on both sides of the argument, aimed at supporting 
the underpinning case for or against the regulatory measure itself. 
 
The contention here is of attempted regulatory chill, but it is difficult to prove whether 
this constitutes an attempt to dissuade further action on tobacco control and if it did 
whether it has in fact led other public authorities away from introducing similar 
legislation. For instance the Canadian Government stepped back from an initial 
commitment to introduce plain packaging in 1994, subsequent to threatened action by 
under the ISDS provision of NAFTA 154. 
                                                             
150 2010 Regulatory chill and the threat of arbitration: a view from political science Kyla Tienhaara 
151 Alongside a Uruguay-Switzerland Bilateral Investment Treaty. 
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Tobacco control is an area where BITs and FTAs have been used by industry to 
challenge the legality as of government initiatives such as plain packaging. ISDS 
provisions have played a significant role in relation to current legal actions, but they are 
not the only legal tool that has been called upon. 
 
The tobacco industry has an established history of opposing the introduction of 
regulatory measures that it believes impacts on its ability to legitimately access markets 
or which undermines its ability to make benefit from its intellectual property155. What is 
evident from past and current legal challenges is that the industry will seek to use 
multiple channels, often in parallel, with FTAs featuring prominently. The most recent 
case of this has been between Philip Morris and the Australian government over the 
introduction of plain packaging for tobacco products in 2011.  
 
The findings in relation to tobacco is that industry will seek to use every available 
regulatory instrument at its disposal which may result in significant resource 
implications for governments (the Australian Government has set up both a Tobacco 
Litigation Task Force in the attorney-general’s department and a similar Plain 
Packaging Task Force) and a consequent increase in regulatory caution within other 
governments.  
 
Many health campaigners point out the need to treat tobacco as a special case – 
quoting the problems that Australia and Uruguay have had over packaging disputes, 
Daniel Huber suggests that “negotiators of the TTP and TTIP must seriously consider 
the advice of civil society advocates to exempt tobacco from the final agreements”156.      
 
Whilst the potential for ‘regulatory chill’ is now widely cited to be a risk by civil society 
groups, there is only limited explicit evidence of public authorities being dissuaded from 
embarking on a regulatory course as a result of an action or threatened action by an 
industry or other stakeholder. One recent paper that undertook a more rigorous 
approach to assessing the impact of BITs on environmental policy, but only found 
“inconsistent and contradictory results regarding the effect of BITs”157. The paper does 
state that “prior to their countries becoming party to additional international investment 
agreements, policy makers in low, lower-middle, and upper-middle income countries 
may benefit from more careful consideration of the implications of signing a BIT.”158 A 
recent study undertaken by Prof. Dr. Christian Tietje, of the University Halle, Germany 
and colleagues for the Netherlands Government focused on the particular impact that 
ISDS provisions could have in generating regulatory chill159. They post amongst other 
the often-cited examples of cases taken against the Canadian Government under the 
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provisions of NAFTA, but conclude that each case provides “a credible prima facie 
case for regulatory chill” and that “proving ISDS was the source of the regulatory chill is 
complex and difficult.” The Tietje study refers to a study published in April 2014 that 
concluded that the vast majority of investor-state claims arise from executive branch 
decisions rather than legislative decisions160.  
 
Regulatory chill has been proposed by a range of stakeholders to be a likely 
consequence of the introduction of TTIP. The consideration of the evidence provides 
only limited support for this contention, but makes clear that the current methods to 
assess ‘regulatory chill’ are in need of further development, and that the concept of 
regulatory chill itself warrants further refinement. It is also the case that agencies and 
bodies concerned with the promotion of public health should, where permitted, engage 
with the development process associated with FTAs and assess prospective 
interventions in order to consider their compatibility with relevant provisions in 
international trade law. When considered as a whole, it is evident that establishing 
evidence of unwarranted regulatory caution is problematic. Establishing a causal link 
between such regulatory caution and the actions of litigant under a FTA or even the 
simple presence of an FTA has not fully been established. 
 
7.2.2 Regulatory Snare 
A second impact of legal action taken against governments under international law can 
be termed ‘regulatory snare’. This is a further aspect of the ‘regulatory chill’ hypothesis 
that focuses on the impact on governments that become involved in legal challenge to 
regulation brought about under international law. 
 
The regulatory snare aspect of this case has two elements. Firstly, there is the physical 
legal process, which can stop the implementation of a policy. This is the current 
situation in relation to minimum alcohol pricing in Scotland. The second aspect of 
regulatory snare is the impact on public authorities and other stakeholder groups, with 
respect to the resource and cost impact of having to deal with often protracted legal 
proceedings. 
 
The concept of regulatory snare has been developed as part of this review process. 
Whilst it is evidently the case that governments can and do find themselves 
preoccupied with regulatory issues and facing significant costs and administrative 
commitment, it is important to add a further level of consideration as to whether such 
an impact can be considered to be unreasonable or even if it can be considered to 
constitute in and of itself a means to inappropriately impact upon government, rather 
than it simply being a by-product of the process of law making. Such an assessment 
will require further consideration and research.  
 
7.2.3 Summary Assessment 
It is clear that industry has demonstrated that it will seek to challenge public health 
related regulation and that international trade law provides a range of platforms to 
facilitate such a challenge. Whilst WTO legislation continues to be used it is FTAs and 
most particularly the ISDS provisions within BITs such as TTIP that are most regularly 
accessed in order to take cases forward. 
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However, whilst the evidence review has identified attempts by industry to challenge 
proposed new public health regulation, elements of which could be deemed to be at the 
boundaries of legitimacy, few recent examples have been found of such attempts being 
successful in dissuading governments from their chosen regulatory path. 
 
Stakeholder groups continue to view TTIP as providing an enhanced platform to 
challenge the right to regulate. Yet an examination of the evidence brings into question 
the extent to which ISDS within TTIP would represent a fundamental change in the 
international legal framework and whether a negotiated ‘ISDS’ could in fact provide an 
improved framework to that offered by the ISDS provisions within the existing 
patchwork of BITs affecting European Member States.  
 
ISDS provisions within TTIP now appear likely to face removal or modification, but 
even if this does prove to be the case public health policy and regulation will continue 
to face legal challenge through the existing legal framework. 
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8.0 Governance and Accountability 
The TTIP negotiating process is more open than for prior FTAs, partly by design and 
partly as a response to growing stakeholder and public comment. TTIP additionally 
includes a more developed governance structure than is usual for FTAs, reflecting the 
commitment of the negotiating partners to the establishment of a ‘living agreement’.   
8.1 Overview of TTIP Governance 
Government and business have historically led FTAs, with civil society and other 
stakeholders making the majority of representations outside the formal decision making 
structures. Assessment of the governance structures of NAFTA is that the 
establishment of a Free Trade Commission and Secretariat have been of limited 
impact161. 
 
TTIP partially aligns to this pattern in that the majority of the negotiating process has 
taken place exclusively on a state-to-state basis, although TTIP involves more 
structured and ad hoc consultation with stakeholder organisations and the wider public 
than has historically been the case with other FTA negotiating processes. The two 
distinguishing elements are: 
 
§ Structured Engagement - TTIP has a built in thematic governance structure that 
will continue in existence after ratification with an on-going remit to support 
further regulatory cooperation; and 
§ Ad Hoc Engagement - TTIP has seen additional formal consultation exercises 
undertaken in relation to the potential impact on SMEs and to gather views on 
the inclusion of ISDS as the arbitration mechanism within the Investment 
Chapter. 
 
Whilst discussions on TTIP remain guarded it is apparent that there are provisions to 
set up internal regulatory governance structures. Firstly there is the TTIP Oversight 
Body, to which a series of sub-committees would report. The Transatlantic Regulatory 
Cooperation Council (TRCC) would bring together representatives of regulatory 
agencies in the EU and US to monitor the implementation of commitments made under 
TTIP and consider new priorities for regulatory cooperation including joint development 
of future regulations. The relationship of TRCC to government and broader democratic 
structures is yet to be fully set out. 
 
In addition there are likely to be Joint Management Committees to discuss concerns 
about particularly themes such as SPS. However, the review found little information 
about how this committee would function and how it would relates to the ISDS 
mechanism.  
8.2 Civil Society Engagement 
Despite there being limited structured opportunities for the formal engagement of civil 
society groups, TTIP has seen a high level of civil society engagement on both sides of 
                                                             
161 http://www.internationaldemocracywatch.org/index.php/north-american-free-trade-agreement 
 63 
 
the Atlantic. There is a TTIP Advisory Group for invited stakeholder organisations and 
there have additionally been a number of consultation events set up in both Europe 
and the United States at which members of the respective negotiating teams have 
been present. 
 
The engagement of civil society in the TTIP process has been growing in recent 
months, with the first formal public demonstration against TTIP being held in the UK in 
July 2014. Individual campaign groups such as Stop TTIP have sought to challenge 
both individual chapters within TTIP but also the fundamental commitment to a new US 
EU free trade agreement in the form presented. A further development has been an 
attempt to initiate a Citizen Initiative to challenge both CETA and TTIP. Evidence 
suggests that the campaign was close to achieving the required one million signatories 
required to invoke action, but in September 2014 was deemed by the Commission to 
be outside the bounds of the process162.  
8.3 Public Opinion 
The state of public opinion across Europe to TTIP is not easy to assess, although there 
is evidence to suggest broad but limited support for TTIP that is offset by concerns 
being expressed in relation to particular issues such as health and arbitration systems.  
 
Whilst no comprehensive public opinion survey has been undertaken to date in Europe 
or the US concerning TTIP there are a number of interesting studies to consider. 
Firstly, there has been a study for the Atlantic Council and the Bertelsmann Foundation 
who are both explicitly in favour of TTIP. This study surveyed more than 300 
respondents from business, academia, government, legislatures and the media via an 
electronic survey, with participants selected on the basis of their expertise in trade 
policy and familiarity with the issues at hand in the negotiations. Respondents came 
from both the US and Europe, with stakeholders from Washington, Brussels and 
Germany heavily represented163. The survey suggested broad ranging support for 
TTIP, with limited comment made on specific provisions. Further trade specific surveys 
have been undertaken such as that by in Belgium for the American Chamber of 
Commerce in Belgium, which is again supportive of TTIP.164 
 
Another study on TTIP this time undertaken by Pew Research, an independent US 
based think tank, demonstrated that a small majority of US and German voters support 
the overall idea of a transatlantic FTA. However, the survey findings also suggest that 
there is a more critical view, particularly amongst German respondents to specific 
provisions including governance and transparency as well as issues such as food 
standards165. Overall the team behind the study believes that TTIP is suffering from a 
"double deficit” in the form of a lack of understanding combined with a lack of trust.  
 
Finally, a UK study commissioned by the Trade Union UNITE focused on the potential 
impact of TTIP on the National Health Service. This poll of more than 2,600 voters 
across 13 marginal Conservative-held seats, found 68% opposed the inclusion of the 
NHS as part of the deal. Opposition was highest among those planning on voting for 
                                                             
162 http://www.theguardian.com/politics/2014/aug/21/wheres-outrage-transatlantic-trade-investment-partnership 
163 http://www.bfna.org/sites/default/files/publications/2014%20TTIP%20Stakeholder%20Survey_web.pdf 
164 https://www.surveymonkey.com/s/2K2YQQ3 
165 http://www.pewglobal.org/2014/04/09/support-in-principle-for-u-s-eu-trade-pact/ 
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Labour (78%) or the United Kingdom Independence Party (77%), but even among 
Conservative supporters only 23% backed the inclusion of the NHS in TTIP166. 
 
The Pew study also raised the issue as to whether the European Commission should 
be leading European negotiations, with a majority of German respondents believing not 
and arguing for a repatriation of powers to Berlin.  
8.4 Summary Assessment 
The TTIP negotiating team followed an established route in providing only limited 
transparency, which has led with a widely held belief that a ‘legitimacy gap’ has rapidly 
developed. Current public consultations on issues such as ISDS are unlikely to 
assuage a range of critical stakeholder groups and there is increasing evidence of 
discontent bleeding into national political debate.  
 
The broader political debate appears to currently be more balanced with centre-left and 
centre-right governments and opposition parties broadly supporting TTIP. Only more 
leftist and green parties are siding with civil society in complete or partial opposition to 
TTIP, alongside a number of far right parties such as Liga Norda in Italy and Vlaams 
Belang in Belgium. Given the apparent delay to the original timetable that would have 
seen TTIP concluded by the end of 2014, this could change most particularly if public 
opinion turns more explicitly against TTIP.  
 
The most recent admission by European Commission representatives that the process 
needs to be opened up could be seen as a valuable concession or as being too little 
too late. The European Ombudsman is currently undertaking a public consultation in 
relation to transparency and public participation in TTIP, as part of one of two own-
initiative inquiries launched on July 29 against the Council and Commission167. The 
original timescales for TTIP envisaged conclusion in 2014 but with the timescales now 
extended into 2015 pressure continues to grow for a more open and inclusive policy 
development and implementation process. The argument in support of significantly 
greater levels of transparency and involvement are underpinned not only by the 
immediate ambition of TTIP and its focus on non-tariff based reform, but as importantly 
on the commitment to TTIP being a ‘living agreement’. 
 
  
                                                             
166 http://www.theguardian.com/society/2014/aug/07/voters-want-nhs-exempt-us-trade-pact-ttip-eu-privatisation 
167 http://ttip2014.eu/blog-detail/blog/Public%20consultation%20Ombudsman%20TTIP.html 
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9.0 Study Recommendations 
Neither trade compliant public health nor healthy trade agreements provide any 
guarantee of achieving a balance between trade and health. Yet it is evident that the 
potential for international trade and health law to conflict is growing and as such there 
is a clear need for increased dialogue and engagement.  
 
Whilst it must be noted that there remains a significant resource imbalance between 
industry interests by comparison with public health groups, it is also evident that a 
dialogue has been started as part of the TTIP process that there would be value in 
developing. Evidence would suggest that the issue could be addressed in the following 
manner. 
9.1 Healthy trade agreements 
The public health community can contribute to the design of ‘healthy trade agreements’ 
by ensuring that health considerations are fully taken into account at the development 
stage. This would involve enabling provisions to support regulation for public health 
and ensuring that adverse consequences associated with other chapters and 
provisions are avoided or mitigated.  
 
These kinds of negotiations require lawyers, health policy officials and trade officials 
who are all experts in their own fields and fully conversant with the other disciplines. 
Such collaboration also requires a government mandate as well as the creation of 
institutional mechanisms for ongoing cooperation. An additional challenge is that the  
negotiations themselves have been undertaken behind closed doors with only limited 
scope for constructive engagement.  
 
For TTIP to have the potential to be a ‘healthy trade agreement’ there is a need to 
establish a meaningful platform for engagement between relevant stakeholder groups 
and a governance structure that can consider how best to reconcile areas of difference. 
Ultimately this must be a democratic process as it involves decisions regarding policy 
priorities and long-term goals.  Such a process must also recognise the need for 
investment and support so as to ensure that issues of resource asymmetry are 
addressed and critical voices are given support to ensure that both current and future 
dialogue is made credible and meaningful. 
 
There is a need to establish how FTAs such as TTIP can be seen to align to the 
development of global health policy and programmes. The WHO has developed a 
strategic framework around health systems, which they define as “all the organizations, 
institutions, resources and people whose primary purpose is to improve health168”. 
Consideration should be given as to how these global structures can be used to 
connect to the development of regional trade policies such as TTIP. 
                                                             
168 http://www.who.int/healthsystems/about/en/ 
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9.2 Trade compliant public health 
In developing public health strategies that seek to utilise pricing or other regulatory 
levers, it appears to make sense for health policy officials to work closely with trade 
officials to ensure that flexibilities can be built into trade law and fully utilised. For 
example, if there are ways of regulating access to unhealthy foods, alcohol and 
tobacco in a manner that is consistent with the broader objectives of TTIP, then it 
makes sense to explore these. 
 
Certain principles need to be followed to ensure that a policy is compliant with existing 
national, European and international law. Free trade agreements add a further level to 
this process, yet many of the basic provisions will be common. There is a particular 
challenge in that the European Union has limited competency within the health arena. 
That having been said it has established infection control function in ECDC and public 
health is also relatively well established. On this basis it would make sense to seek to 
future proof initiatives such as TTIP by developing potential scenarios that could see 
for example how increased consumption of unhealthy products may be manifested and 
consider how various public policy interventions that could help address associated 
problems.  
 
This approach focuses on public health agencies proactively assessing how different 
interventions could be impacted by provisions in international trade agreements such 
as TTIP and seeking to adopt interventions that have the lowest chance of coming into 
conflict. The recent decision by the UK government of a ‘minimum floor pricing’ for 
alcohol is an example of such a potentially trade compliant policy. The extent to which 
this can be considered a ‘win win’ will be dependent on how effective such measures 
are in achieving their stated public health objectives. 
9.3 Summary Assessment 
The purpose of this report has been to objectively assess existing evidence on the 
potential impact of TTIP on the health of Europe’s 500 million citizens. Very limited 
evidence was found of direct potential health benefits, whilst the indirect effect of any 
broader economic growth that may result from TTIP are likely to be highly dependent 
on how any increase in GDP is deployed, and more particularly on how it can help to 
foster innovation in health goods and services.  
 
By comparison the risks from TTIP do carry with them the potential to reduce health 
outcomes and negatively impact on the ability of government to regulate for public 
health improvement. Yet in most cases the proposed provisions within TTIP are likely 
to compound rather than create problems and the policy development process has 
started a dialogue with regards to how best to marry trade and health goals. 
